Thermostable Vaccine Compositions and Methods of Preparing same

ABSTRACT

Compositions relating to thermostable vaccines and methods of preparing the same. Specifically, methods of preparing thermostable vaccines based on a recombinant ricin neurotoxin protein and uses of co-adjuvants to develop a composition capable of eliciting an immune response in a subject.

RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.13/474,661, filed May 17, 2012, which claims the benefit of priorityfrom U.S. Provisional Application No. 61/487,206, filed on May 17, 2011,the entire contents of which are herein incorporated by reference.

GOVERNMENT SUPPORT STATEMENT

This invention was made with government support under grantUO1-A1-08-2210 from the National Institutes of Health. The governmenthas certain rights in the invention.

FIELD OF THE INVENTION

The present invention relates generally to the field of dried vaccinecompositions. More specifically, to methods of producing dried vaccinecompositions bound to adjuvant and containing immunostimulatorymolecules.

BACKGROUND OF THE INVENTION

Vaccines containing recombinant proteins benefit from or absolutelyrequire an adjuvant to elicit an immune response. (Callahan et al.,1991, The importance of surface charge in the optimization ofantigen-adjuvant interactions, Pharm. Res. 8(7):851-858; Singh andO'Hagan 1999, Advances in vaccine adjuvants, Nat Biotechnol 17(11):1075-81; and O'Hagan et al., 2001, Recent developments in adjuvants forvaccines against infectious diseases, Biomol Eng 18(3): 69-85).Aluminum-salt adjuvants are currently the most widely used adjuvants forgeneral use in humans because of the extensive history of safe use invaccines administered to children and adults. The only adjuvantscurrently appearing in FDA-approved vaccines are the aluminum saltadjuvants, aluminum hydroxide and aluminum phosphate. Aluminum-saltadjuvants enhance the immunogenicity of vaccines and cause significantimprovements in the outcomes of vaccination by reducing the dose levelof protein in vaccine, elevating the titers of protective antibodies,and reducing the need for annual vaccination after a primary series ofvaccination has been completed. Nonetheless, there are significantlimitations in the use of aluminum-salt adjuvants in many subunitvaccines based on recombinant proteins, peptides, and chemicallysynthesized vaccines. These limitations include the general aspects ofvaccine storage and stability, since vaccine containing aluminumadjuvants can be stored only within narrow temperature ranges, andcannot be frozen. Further limitations include the generally acceptedview that aluminum adjuvants are relatively weak, do not foster thedevelopment of cellular immunity, and may favor the development ofantibodies that are non-neutralizing in cases where neutralizingantibodies are necessary to block viral infections or impede theactivity of biological toxins.

In the case of aluminum adjuvants, it has been suggested that to provideadequate immunogenicity, antigens must be adsorbed on the surface of theadjuvant. (Gupta et al., 1995, Adjuvant Properties of Aluminum andCalcium Compounds. Pharmaceutical Biotechnology. 6: 229-248; and Whiteand Hem, 2000, Characterization of aluminium-containing adjuvants, DevBiol (Basel) 103: 217-28). This adsorption is typically facilitatedthrough electrostatic interactions between the antigen and adjuvant, andthe formulation pH is usually chosen so that the antigen and adjuvantare oppositely charged (Callahan et al. 1991). The surface charge on theadjuvant also can be modified by surface exchange reactions with buffersalts such as phosphate, succinate, and citrate (Hem and White, 1984,Characterization of aluminum hydroxide for use as an adjuvant inparenteral vaccines. J Parenter Sci Technol, 38(1): p. 2-10; Chang etal., 1997, Role of the electrostatic attractive force in the adsorptionof proteins by aluminum hydroxide adjuvant. PDA J Pharm Sci Technol,51(1): p. 25-9; and Rinella et al., 1996, Treatment of aluminiumhydroxide adjuvant to optimize the adsorption of basic proteins.Vaccine, 14(4): p. 298-300.) The mechanisms of action of aluminum-saltadjuvants are poorly understood, but likely due to several differentmechanisms. (Lindblad 2004. “Aluminium compounds for use in vaccines”Immunol. Cell. Biol. 82(5):497-505; Gupta and Siber, 1995, Adjuvants forHuman Vaccines—Current Status, Problems and Future-Prospects. Vaccine13(14):1263-1276; Gupta and Rost, 2000, Aluminum Compounds as VaccineAdjuvants, In O'Hagan D, editor Vaccine Adjuvants: Preparation Methodsand Research Protocols, ed., Totowa, N.J.: Humana Press Inc. p 65-89;Cox and Coulter, 1997, Adjuvants—a classification and review of theirmodes of action, Vaccine 15(3):248-256). Common proposed mechanisms arethat the adjuvant acts as a depot at the site of injection, wherein theantigen is slowly released after administration. (Cox and Coulter,1997). Another proposed mechanism is that the adjuvant aids in deliveryof the antigen to antigen-presenting cells (Lindblad 2004). A furtherproposed mechanism is that adjuvant serves as an immunostimulator andelicits Th2 cytokines (Grun and Maurer 1989, Different T helper cellsubsets elicited in mice utilizing two different adjuvant vehicles: therole of endogenous interleukin 1 in proliferative responses. CellImmunol 121(1):134-145). Yet another proposed mechanism is that adjuvantdestabilizes protein antigens on the surface of the adjuvant making themmore susceptible to proteolytic degradation (Jones et al., 2005, Effectsof adsorption to aluminum salt adjuvants on the structure and stabilityof model protein antigens. J Biol Chem 280(14):13406-13414; and That etal., 2004. “Antigen stability controls antigen presentation” J. Biol.Chem. 279(48):50257-50266).

Although the mechanism of action is not fully understood, it is likelythat surface area, surface charge, and morphology of the adjuvant areimportant factors dictating the immune response to antigens adsorbedonto these adjuvants (Hem and White 1984). It is generally theorizedthat the smaller the particle size of the vaccine adjuvant, the moreimmunogenic the vaccine preparation, especially when particle size isapproximately 1 micron, a size best suited for uptake into professionalantigen presenting cells (Maa et al., 2003. Stabilization ofalum-adjuvanted vaccine dry powder formulations: mechanism andapplication. J Pharm Sci 92(2):319-332, Diminsky et al., 1999. Physical,chemical and immunological stability of CHO-derived hepatitis B surfaceantigen (HBsAg) particles. Vaccine 18(1-2):3-17).

Lyophilization (freeze drying) is a process frequently utilized toimprove long term stability of various protein preparations. However,when vaccines formulated with aluminum-salt adjuvants are processed inan attempt to improve stability through freezing and lyophilization, aloss of potency occurs, where potency is a summation of the quality ofthe vaccine measurable by a series of tests that can includeimmunogenicity in animals, chemical degradation of protein antigen,denaturation of protein antigen, or loss of substituent immunogenicepitopes. Loss of potency is associated with loss of efficacy in humans.Previous studies have suggested that a freeze-dried vaccine productcontaining adjuvant cannot be produced due to aggregation of theadjuvant particles. (Diminsky et al., 1999; Maa et al., 2003). A numberof theories have been set forth to explain possible mechanismsresponsible for the loss of potency following lyophilization of vaccinesformulated with aluminum-salt adjuvants. Particle aggregation mayaccount for significant losses. For example, the aggregation of aluminumhydroxycarbonate and magnesium hydroxide gels after freezing and thawinghas been attributed to ice crystal formation which forces particlestogether, resulting in irreversible aggregation. (Zapata et al., 1984,Mechanism of freeze-thaw instability of aluminum hydroxycarbonate andmagnesium hydroxide gels. J Pharm Sci 73(1):3-8). This explanation hasbeen proposed by Maa et al., 2003 suggesting further that faster coolingrates result in a greater rate of ice nucleation and the formation ofsmaller ice crystals, which would not force aluminum particles into anaggregate. Particle aggregation can thus account for losses of potency,but other factors, such as loss of protein configuration (tertiarystructure), loss of protein secondary structure, and modifications ofprimary structure through deamidation or oxidation of amino acid sidechains.

The capacity of particles to increase allergic sensitization ispredicted by particle number and surface area, not by particle mass.Moorefield et al. showed that the degree of antigen internalization ofadjuvant particles is inversely related to the particle size of theadjuvant aggregates (Moorefield et al., 2005. “Role ofaluminum-containing adjuvants in antigen internalization by dendriticcells in vitro” Vaccine 23(13):1588-1595). Nygaard et al. showed thatthe particle diameter, and thus surface area and number of particles,and not mass or volume, is the dominant property in the immunologicalresponse of polystyrene particles in mice (Nygaard et al., 2004). Whileit is likely that the particle size is an important characteristicparameter for immunogenicity, there has yet to be a comprehensive studyexamining the particle size distribution (PSD) as a function offormulation and cooling rates along with other physical properties ofthe products produced.

There is some consensus view that the more effective vaccines withaluminum adjuvants are ones in which antigen is bound to the aluminumsurface, rather than free in solution (Lindblad, 2004, Aluminiumadjuvants—in retrospect and prospect, Vaccine, 22:3658-68). Forreproducibility of formulations and stability, it is desirable to defineconditions for optimal binding of antigen to crystal surfaces, andconditions in which antigen does not desorb over time or under elevatedstress conditions. To construct aluminum vaccines, it is necessary tocarry out studies to optimize binding and desorption. Aluminum adjuvantshave a point of zero charge (PZC) at a certain solution pH, but arecharged at pHs above or below this value (White and Hem, 2000,Characterization of aluminium-containing adjuvants, Dev Biol (Basel),103:217-28). Selecting an optimal formulation pH is further complicatedfor a recombinant protein vaccine for which binding to aluminum saltadjuvants is generally required to obtain the desired immune response(McInerney, Brennan et al., 1999, Analysis of the ability of fiveadjuvants to enhance immune responses to a chimeric plant virusdisplaying an HIV-1 peptide, Vaccine, 17:1359-68). To facilitate proteinbinding to adjuvant, a solution pH is selected in which the protein andadjuvant have opposite charges. However, a solution pH that providesoptimal protein stability, may not allow for appropriate binding of thevaccine to adjuvants. In such a scenario, a vaccine protein may have tobe prepared at pH that is suboptimal for stability and lyophilized withappropriate stabilizing excipients to minimize degradation duringlong-term storage.

Lyophilization of proteins to stabilize structure and activity forstorage and reconstitution has been commonly applied to recombinantprotein therapeutic proteins. This has been usually accomplished byfreeze drying in the presence of disaccharides such as trehalose andother excipients that promote a glass state during process and storage.Proteins can be stored for long term as long as the product is storedbelow its glass transition temperature (T_(g)) above which the materialtransitions into a rubbery state. Excipients are thought to stabilizeprotein in the amorphous state through interactions of the stabilizerwith specific sites substituting for water during drying and bysimultaneously suppressing translational and rotational motions of theprotein molecule (α-relaxations) or portions of the molecule(β-relaxations). Drying technology has been less frequently applied tolong term storage of vaccines, especially in the case of vaccinesadsorbed to aluminum phosphate or aluminum hydroxide adjuvants. Verylittle data is available on the storage of dried vaccines under elevatedtemperature conditions, as most of the attempts to generate driedvaccines have been to obtain inhalable powders or preparations able tosurvive moderate excursions in temperature. For example, because theyellow fever vaccine is use primarily in tropical climates,lyophilization in the presence of stabilizers (lactose, sorbitol) hasbeen used to preserve viability of the live virus vaccine (Monath, 1996,Stability of yellow fever vaccine, Dev Biol Stand, 87:219-25). Withoutexcipients during lyophilization and storage, activity is rapidly lostabove −20° C., but the stabilized vaccine can withstand more than twoweeks at 37° C. A lyophilized dried vaccine for the cattle diseaserinderpest has also been developed and can be employed for up to a monthafter leaving the cold chain in African field conditions (House andMariner, 1996, Stabilization of rinderpest vaccine by modification ofthe lyophilization process, Dev Biol Stand, 87:235-44). Similar attemptsto use variations on process and drying have been recently applied tomeasles vaccine development (Burger, Cape et al., 2008, Stabilizingformulations for inhalable powders of live-attenuated measles virusvaccine, J Aerosol Med Pulm Drug Deliv, 21:25-34; Burger, Cape et al.,2008, Stabilizing Formulations for Inhalable Powders of Live-AttenuatedMeasles Virus Vaccine, J Aerosol Med) and for dried vaccine powders forinfluenza where it is likely very important to devise conditions thatpermit retention of the structure of the immunogen (Amorij, Meulenaar etal., 2007, Rational design of an influenza subunit vaccine powder withsugar glass technology: preventing conformational changes ofhaemagglutinin during freezing and freeze-drying, Vaccine, 25:6447-57;Amorij, Huckriede et al., 2008, Development of Stable Influenza VaccinePowder Formulations: Challenges and Possibilities, Pharm Res). As astabilizer, small amounts of formaldehyde are occasionally added tovaccines, including the current AVA anthrax vaccine (Biothrax®), and mayact by cross-linking proteins forming more immunogenic proteinaggregates on the surface of aluminum crystals (Little, Ivins et al.,2007, Effect of aluminum hydroxide adjuvant and formaldehyde in theformulation of rPA anthrax vaccine, Vaccine, 25:2771-7). Formaldehydehad been used historically as the stabilizer of choice in the oldervaccines derived from culture supernatants, such as tetanus toxoid,botulinum toxoids, and others. The current AVA vaccine is labeled for 3year stability, where stability is a function of a number of biochemicalevaluations and potency. Although a moderate amount of stability can beachieved with liquid suspension vaccines, it is not likely that allstability parameters can be met for longer storage periods that arerequired for vaccines to be stockpiled and distributed.

Successful drying of therapeutic proteins, while retaining structure andfunction, is dependent on the knowledge of the degradation pathways thatoccur in solution, which can be retarded or eliminated by appropriatedrying and excipients for stabilization. For vaccines, function islargely determined by immunogenicity and protection studies, rather thanenzymatic activity. In the case of protein immunogens that are adsorbedto aluminum adjuvants crystals, the measurement of function and otherparameters in vitro is correspondingly more difficult, since protein maybe sequestered and difficult to remove for analysis. Thus, function canonly be tested by immunogenicity and protection studies. The tertiaryconformation of proteins can obviously affect enzymatic functions, ifpresent, but also can affect immunogenicity of B cell epitopes dependenton conformation. Linear B and T cell epitopes contained therein can bealso affected by oxidation (of methionine and cysteine residues) anddeamidation (especially of asparagine residues). pH is one of the mostcritical formulation variables governing stability of therapeuticproteins. (Carpenter, Chang et al., 2002, Rational design of stablelyophilized protein formulations: theory and practice, Pharm Biotechnol,13:109-33; Chi, Krishnan et al., 2003, Physical stability of proteins inaqueous solution: mechanism and driving forces in nonnative proteinaggregation, Pharm Res, 20:1325-36) By affecting the conformational andcolloidal stability of proteins in solution, pH can greatly modulatetheir aggregation rates (Chi, Krishnan et al., 2003, Physical stabilityof proteins in aqueous solution: mechanism and driving forces innonnative protein aggregation, Pharm Res, 20:1325-36). In addition,rates of deamidation are strongly dependent on pH (Manning, Patel etal., 1989, Stability of protein pharmaceuticals, Pharm Res, 6:903-18).There can be different optimal pH values for physical and chemicalstability for a given protein (Kolvenbach, Narhi et al., 1997,Granulocyte-colony stimulating factor maintains a thermally stable,compact, partially folded structure at pH2, J Pept Res, 50:310-8). Forexample, physical stability may be optimal at a pH where deamidation isunacceptably rapid (Chang, Reeder et al., 1996, Development of a stablefreeze-dried formulation of recombinant human interleukin-1 receptorantagonist, Pharm Res, 13:243-9). In such cases, development of alyophilized formulation where the rates of these reactions are minimizedmay provide a viable strategy to obtain a stable product. The fewpublished studies examining effects of pre-lyophilization solution pH onthe stability of therapeutic proteins during lyophilization and storagein dried formulations demonstrated the importance of this parameter(Prestrelski, Pikal et al., 1995, Optimization of lyophilizationconditions for recombinant human interleukin-2 by dried-stateconformational analysis using Fourier-transform infrared spectroscopy,Pharm Res, 12:1250-9; Chang, Reeder et al., 1996, Development of astable freeze-dried formulation of recombinant human interleukin-1receptor antagonist, Pharm Res, 13:243-9; Katayama, Kirchhoff et al.,2004, Retrospective statistical analysis of lyophilized proteinformulations of progenipoietin using PLS: determination of the criticalparameters for long-term storage stability, J Pharm Sci, 93:2609-23).These studies demonstrated the difficulty in identifying apre-lyophilization solution pH that confers adequate physical andchemical stability to the proteins studied during lyophilization andstorage. However, degradation of proteins could be minimized ifsufficient amounts of stabilizing excipients are included in theformulation. For example, when recombinant human interleukin-1-receptorantagonist (rhIL-1ra) was formulated prior to lyophilization in asolution containing suboptimal sucrose at levels less than 0.3 massratio of sucrose/protein and at pH less than 6.5, severe proteinaggregation occurred after lyophilization, during storage andreconstitution (Chang, Reeder et al., 1996, Development of a stablefreeze-dried formulation of recombinant human interleukin-1 receptorantagonist, Pharm Res, 13:243-9). Protein aggregation was minimizedfollowing lyophilization from a solution at pH greater than 6, although,deamidation occurred at an unacceptably high rate. Followinglyophilization from a solution containing amounts of sucrose greaterthan 0.3 sucrose/protein mass ratio at pH 6.5, both destabilizationpathways could be inhibited. In another example, interleukin-2 (IL-2)had significantly greater structural perturbation during freeze-dryingat pH 7, which resulted in higher levels of aggregation after storageand rehydration than samples lyophilized from solutions at pH 5(Prestrelski, Pikal et al., 1995, Optimization of lyophilizationconditions for recombinant human interleukin-2 by dried-stateconformational analysis using Fourier-transform infrared spectroscopy,Pharm Res, 12:1250-9). The addition of sucrose to the pre-lyophilizationsolution formulation at pH 7 improved the stability of IL-2 duringstorage following lyophilization. More recently, this approach topre-formulation has been taken with anthrax rPA to create a dried powdervaccine candidate for nasal administration (Jiang, Joshi et al., 2006,Anthrax vaccine powder formulations for nasal mucosal delivery, J PharmSci, 95:80-96). In this case, conditions for optimizing pH and excipientstabilizers were established for rPA in solution prior tolyophilization. As trehalose was one of the excipients determined tostabilize soluble rPA to thermal stress, there was evidence of at least30 days stability at 40° C. for the dried trehalose-containing vaccinesin terms of the total content of rPA in comparison to liquid samples inwhich rPA quickly disappeared. In an effort to obtain a dried powdercomposition for epidermal delivery using a gas-driven injection device,it was found that rapid freezing of aluminum-adsorbed hepatitis Bvaccine (HBsAg) in the presence of a mixture of mannitol, glycine, anddextran (not more than ˜6% w/v of total excipients) resulted in vaccinesthat retained particle size and relative immunogenicity in mice after arapid freezing (spray freeze drying) that involved injection of thesprayed vaccine into liquid nitrogen prior to drying (Maa, Zhao et al.,2003, Stabilization of alum-adjuvanted vaccine dry powder formulations:mechanism and application, J Pharm Sci, 92:319-32). The behavior of thespray-freeze dried vaccines under thermal stress conditions was notdetermined, although normally lyophilized vaccine aggregated afterprocessing and was minimally immunogenic. Diminished immunogenicity wasassociated with aluminum particle aggregation after reconstitution.

More lately, Roser et al. have suggested lyophilization methods thatwill prevent aggregation of aluminum particles. Roser et al., U.S. Pat.No. 6,890,512 disclose a method of preventing gross aggregation duringdehydration and rehydration of particulates in suspension by adding to aparticulate suspension of aluminum hydroxide in excess of 15% (w/v) oftrehalose. Trehalose, alpha.-D-glucopyranosyl-alpha-D-glucopyranoside,is a naturally occurring disaccharide responsible for protection ofplant cells from desiccation. Trehalose has been shown to preventdenaturation of proteins during desiccation by forming sugar glassesthat immobilize protein structure. However, Roser et al., whiledisclosing prevention of gross particle aggregation, do not disclose theimportance of freezing rate of a particulate suspension or other factorscritical to control and maintain pre-lyophilization particle size andprotein structure in an aluminum-salts containing vaccine in thepresence of trehalose. Maintenance of particle size is a criticalparameter in controlling the degree of adsorption of protein immunogensto the surface of aluminum particles, and is influenced by severalfactors during lyophilization cycle in addition to the content oftrehalose or other glassifying excipients. These factors influence theimmunogenicity and generation of protective immune responses.

Aluminum-salt adjuvants provide a well explored means to augment theimmunogenicity of protein or peptide subunit vaccines. However, avariety of exploratory formulations to enhance vaccines have beendeveloped as more potent alternative to aluminum-salts adjuvants, butare not currently available in FDA-licensed human vaccines. Formulationsdesigned to enhance immune responses include a variety of compositionsbased on water-in-oil emulsions, oil-in-water emulsions, self-assemblingmacrostructures, cytokines, saponins, toll-like receptor agonists(TLR-4, TLR-5, and TLR-9), immunostimulatory double stranded RNAspecies, unmethylated DNA oligonucleotides, and polymeric microparticlesand nanostructures. Many of these compositions are directed towardsimproving the immunogenicity of injected vaccines, and some variationscan be applied to altering routes of delivery for intranasal or oralvaccination. As an example of one class of immunostimulatory moleculesthat can be used to enhance vaccine immunogenicity, bacterial DNA, butnot vertebrate DNA, can be used because of direct immunostimulatoryeffects that activate lymphocytes. This is due to unmethylated CpGdinucleotides are present at the expected frequency in bacterial DNA butare under-represented and methylated in vertebrate DNA (Krieg et al.,1995). Activation may also be triggered by addition of syntheticoligodeoxynucleotides (ODN) that contain an unmethylated CpGdinucleotide in a particular sequence context. CpG DNA inducesproliferation of almost all (>95%) B cells and increases immunoglobulin(Ig) secretion. This B cell activation by CpG DNA is T cell independentand antigen non-specific. However, B cell activation by lowconcentrations of CpG DNA has strong synergy with signals deliveredthrough the B cell antigen receptor for both B cell proliferation and Igsecretion (Krieg et al., 1995). This strong synergy between the B cellsignaling pathways triggered through the B cell antigen receptor and byCpG DNA promotes antigen specific immune responses. In addition to itsdirect effects on B cells, CpG DNA also directly activates monocytes,macrophages, and dendritic cells to secrete a variety of cytokines,including high levels of IL-12 (Klinman et al., 1996; Halpern et al.,1996; Cowdery et al., 1996). These cytokines stimulate natural killer(NK) cells to secrete gamma-interferon (IFN-.gamma.-) and have increasedlytic activity (Klinman et al., 1996, supra; Cowdery et al., 1996,supra; Yamamoto et al., 1992; Ballas et al., 1996). Overall, CpG DNAinduces a Th1 like pattern of cytokine production dominated by IL-12 andIFN-gamma with little secretion of Th2 cytokines (Klinman et al., 1996).Other molecules stimulate toll like receptors. One example is flagellin,the protein subunit comprising numerous bacterial flagella. Flagellin isa TLR-5 ligand and triggers at least one of the biological functions ofantigen presenting cells upon such binding. Flagella are found on thesurface of rod and spiral shaped bacteria, including members of thegenera Escherichia, Salmonella, Proteus, Pseudomonas, Bacillus,Campylobacter, Vibrio, Treponema, Legionella, Clostridia, andCaulobacter. The conserved regions of flagellins are important for TLR5binding, while the polymorphic central region can be deleted withoutaffecting binding to TLR5. Flagellin sequences from numerous bacteriaare available in the art, such as Genbank accession numbers D13689,YP.sub.--275549, YP.sub.--275550, AAU18718, AAU18717, ZP.sub.--00743095,EA052626, YP.sub.--315348, AAT28337, AAT28336, AAT28335, AAT28334,AAT28333, AAZ36356, AAZ33167, AAZ94424, AAZ91670, NP.sub.--414908,BAD18052, and BAD18051. As a third example of purified adjuvant immunestimulants, non toxic chemically synthesized or enzymatically modifiedderivatives of gram negative lipopolysaccharides are potent adjuvantsand act by stimulating lymphocytes through TLR-4 binding and activation.For example, monophosphoryl lipid A (MPL) is a derivative of the lipid Acomponent of lipopolysaccharide and is a potent activator ofpro-inflammatory cytokines. Although native lipid A and its parent LPShave powerful pyrogenic properties and in humans induce febrileresponses (Greisman and Homick, J Immunol, 109:1210-1215 (1972);Greisman and Homick, J Infect Dis, 128:257-263 (1973); Abemathy andSpink, J Clin Invest, 37:219-225 (1958); Rietschel et al, supra; andRaetz, supra (1993)), MPL and its chemically synthesized analogues arenot toxic but induce a compendium of host proinflammatory cytokinesincluding IL-1, IL-6, and TNF-alpha.

In addition, to enhance the immune response to subunits adsorbed toaluminum salts, it is likely that co-adjuvants will be required in orderto generate effective antibody responses in humans after one or twodoses. A number of adjuvant compounds that are compatible with aluminumsalts have been evaluated as adjuvants in recent years. Primarily theseadjuvants include Monophosphoryl Lipid A (MPL) and QS-21, and CpGsequences. Recent data with anthrax vaccine indicates in human studiesthat AVA, an AlOH adsorbed vaccine, can be significantly enhanced byadding CpG 7909 to the adjuvant formulations in non-human primates andhumans, in terms of total anti-rPA antibodies and anthrax toxinneutralizing antibodies, although no data describe the long term thermalstability of CpG-containing vaccines (Klinman, 2006, CpGoligonucleotides accelerate and boost the immune response elicited byAVA, the licensed anthrax vaccine, Expert Rev Vaccines, 5:365-9). MPLand QS-21 have been also used with aluminum salts as well as inproprietary oil emulsion formulations being developed by Glaxo SmithKline Biologics. QS-21 has been evaluated in AlOH vaccines in humans andanimal models with good evidence of tolerability and systemic safety.QS-21 is thought to bind to aluminum salts through ionic and hydrophobicinteractions, as well as some part of it remaining in solution (inaqueous vaccines) in a micellar form. QS-21 is a saponin purified fromtree bark with broad adjuvant effects to induce both antibody and cellmediated immunity. Though the mechanism is not understood, dose levelseffective in conjunction with human vaccines have been evaluated. QS-21with aluminum has been evaluated in clinical studies and independentsafety studies of QS-21 formulated with antigens have been studied.QS-21 has been associated with stinging at the site of injection (thatresolves), with very little evidence of systemic side effects (Waite,Jacobson et al., 2001, Three double-blind, randomized trials evaluatingthe safety and tolerance of different formulations of the saponinadjuvant QS-21, Vaccine, 19:3957-67). Several studies in humans haveshown that QS-21 enhances responses to antigens that are adsorbed toaluminum. These include several trials in malaria vaccine candidates(Nardin, Oliveira et al., 2000, Synthetic malaria peptide vaccineelicits high levels of antibodies in vaccinees of defined HLA genotypes,J Infect Dis, 182:1486-96; Kashala, Amador et al., 2002, Safety,tolerability and immunogenicity of new formulations of the Plasmodiumfalciparum malaria peptide vaccine SPf66 combined with the immunologicaladjuvant QS-21, Vaccine, 20:2263-77), HIV gp120 (Evans, McElrath et al.,2001, QS-21 promotes an adjuvant effect allowing for reduced antigendose during HIV-1 envelope subunit immunization in humans, Vaccine,19:2080-91) and more recently Rhesus macaque trials of Dengue virussubunits in which neutralizing titers and protection were enhanced byQS-21 (Putnak, Coller et al., 2005, An evaluation of dengue type-2inactivated, recombinant subunit, and live-attenuated vaccine candidatesin the rhesus macaque model, Vaccine, 23:4442-52). The solutionstability of QS-21 has been well studied under long term stabilitystudies, and has shown that adjuvant active QS-21 (which actuallyconsists of two isomeric forms) is highly stable in slightly acidicbuffers for over 4 years, whereas less than 10 days at 40° C. (Kensiland Kammer, 1998, QS-21: a water-soluble triterpene glycoside adjuvant,Expert Opin Investig Drugs, 7:1475-82). QS-21 is stored as a driedpowder and in that form is stable indefinitely.

Ricin toxin is a 64 kDa protein produced by castor beans (Ricinuscommunis) (Doan L G. Ricin: mechanism of toxicity, clinicalmanifestations, and vaccine development. A review. Journal ofToxicology—Clinical Toxicology 2004; 42(2):201-8; Audi J, Belson M,Patel M, Schier J, Osterloh J. Ricin poisoning: a comprehensive review.JAMA 2005; 294(18):2342-51). The holotoxin consists of two polypeptidechains (A and B) joined by a disulfide bond. The A chain (RTA) is aribosome inactivating protein (RIP) that inhibits protein synthesis inmammalian cells. The B chain (RTB) is a lectin that binds to galactoseresidues on the surface of cells. Once internalized by a cell, RTAtranslocates into the cytosol where it enzymatically inactivates 60Sribosomes (Smallshaw, J E and Vitetta, E S, A lyophilized formulation ofRiVax, a recombinant ricin subunit vaccine, retains immunogenicity.Vaccine 2010 Mar. 11; 28(12): 2428-2435). A single molecule of RTA inthe cytoplasm of a cell completely inhibits protein synthesis. Thereported estimated lethal dose of ricin in humans is 1-25 m/kg wheninhaled, injected, or ingested (Audi et al). Because of its wideavailability and extraordinary toxicity, ricin represents a potentialagent for use in bioterrorism and is therefore classified by the Centersfor Disease Control, Atlanta Ga. (CDC) as a level B biothreat. Ricinintoxication can be prevented in experimental animals by vaccinationwith toxoid or deglycosylated ricin A chain (dgRTA), or by passiveimmunization with anti-ricin antibodies. However the toxoid isconsidered to be too toxic for routine use in humans and dgRTA isdifficult and expensive to produce, and also retains both active sitesand could induce toxic side effects in humans. Passive immunization withanti-ricin antibodies is only effective if the ricin dose is relativelylow and the antibody is administered within a few hours after exposure(Hewetson J F, Rivera V R, Creasia D A, Lemley P V, Rippy M K, Poli M A.Protection of mice from inhaled ricin by vaccination with ricin or bypassive treatment with heterologous antibody. Vaccine 1993;11(7):743-6).

In order to avoid these limitations, a recombinant RTA vaccine (RiVax)was developed (Smallshaw et al.). RiVax incorporated two pointmutations, Y80A and V76M, to greatly reduce or eliminate both of itsknown toxicities, i.e. ribotoxicity and vascular leak-inducing ability.In the absence of adjuvant, RiVax is non-toxic and immunogenic in mice,rabbits and humans (Smallshaw J E, Firan A, Fulmer J R, Ruback S L,Ghetie V, Vitetta E S. A novel recombinant vaccine which protects miceagainst ricin intoxication. Vaccine 2002; 20(27-28):3422-7). Such amodel has been showed to yield positive results without much of thetoxicity implicated with other vaccine models.

Ricin is currently listed by NIAID and the Centers for Disease Controland Prevention (CDC) as a level B Biothreat agent (Rotz, Khan et al.,2002, Public health assessment of potential biological terrorism agents,Emerging Infectious Diseases, 8:225-30.). The vaccine candidate is basedon a recombinant subunit vaccine against ricin toxin obtained by geneticinactivation of residues in the ricin toxin A chain (RTA) that areinvolved in well characterized activities of the molecule. This modifiedmolecule is immunogenic in mice, rabbits, and humans and inducesantibodies that neutralize the toxin or are involved with clearance ofthe toxin systemically or mucosally in each species. In the case ofsmallpox or anthrax, terrorist induced epidemics could be controlled bymass vaccination, selective vaccination, or ring vaccination afterevidence of an outbreak (Halloran, Longini et al., 2002, Containingbioterrorist smallpox, Science, 298:1428-32; Kaplan, Craft et al., 2002,Emergency response to a smallpox attack: the case for mass vaccination,Proc Natl Acad Sci USA, 99:10935-40; Bozzette, Boer et al., 2003, Amodel for a smallpox-vaccination policy, N Engl J Med, 348:416-25;Kretzschmar, van den Hof et al., 2004, Ring vaccination and smallpoxcontrol, Emerg Infect Dis, 10:832-41). On the other hand, vaccinationagainst bioterrorist exposure to biological toxins, because the agentsdo not replicate, is more likely to be used in select populations, suchas the military or first responders, rather than mass vaccination. Theisolated A and B subunit of ricin can be produced in E. coli and otherrecombinant hosts. The B chain is also a candidate for inclusion in avaccine, but is considered less immunogenic and less protective than theA chain (Maddaloni, Cooke et al., 2004, Immunological characteristicsassociated with the protective efficacy of antibodies to ricin, Journalof Immunology, 172:6221-8). Although ricin A chain is at least 1000-foldless toxic than the native ricin, it still retains enzymatic activitythat may result in toxicity when used as a vaccine (Thorpe, Detre etal., 1985, Modification of the carbohydrate in ricin withmetaperiodate-cyanoborohydride mixtures. Effects on toxicity and in vivodistribution, European Journal of Biochemistry, 147:197-206.). Severalkey amino acid residues in ricin A chain, Y80, Y123, E177, R180, N209,and W211, constitute its enzymatically-active site (Olson, 1997, RicinA-chain structural determinant for binding substrate analogues: amolecular dynamics simulation analysis, Proteins, 27:80-95.; Lebeda andOlson, 1999, Prediction of a conserved, neutralizing epitope inribosome-inactivating proteins, International Journal of BiologicalMacromolecules, 24:19-26). Mutations in some of these amino acidresidues have yielded ricin A chains with negligible toxicity asdetermined by the inhibition of protein synthesis (Kim and Robertus,1992, Analysis of several key active site residues of ricin A chain bymutagenesis and X-ray crystallography, Protein Engineering, 5:775-9.).An additional site and residues involved in the binding of RTA toendothelial cells have also been identified, which occur extracellularlyand do not require toxin entry into host cells (Baluna and Vitetta,1999, An in vivo model to study immunotoxin-induced vascular leak inhuman tissue, J Immunother, 22:41-7; Baluna, Coleman et al., 2000, Theeffect of a monoclonal antibody coupled to ricin A chain-derivedpeptides on endothelial cells in vitro: insights into toxin-mediatedvascular damage, Exp Cell Res, 258:417-24; Smallshaw, Ghetie et al.,2003, Genetic engineering of an immunotoxin to eliminate pulmonaryvascular leak in mice, Nature Biotechnology, 21:387-91). The endothelialbinding site on RTA is implicated in the damage to isolated HUVEC cellsand to the induction of vascular leak syndrome (VLS), which has beendetermined to be a dose limiting toxicity in the use of RTA-containingimmunotoxins (Smallshaw, Ghetie et al., 2003, Genetic engineering of animmunotoxin to eliminate pulmonary vascular leak in mice, NatureBiotechnology, 21:387-91). The portion of RTA involved in both pulmonaryvascular leak, vascular leak in human skin xenografts in SCID mice, andHUVEC cells appears to involve amino acid residues L74, D75, and V76(Baluna, Rizo et al., 1999, Evidence for a structural motif in toxinsand interleukin-2 that may be responsible for binding to endothelialcells and initiating vascular leak syndrome, Proceedings of the NationalAcademy of Sciences of the United States of America, 96:3957-62.).Therefore, an A chain vaccine taking into account those toxic sites hasbeen constructed and comprises a double mutant of ricin A chain.Tyrosine 80 is mutated to alanine in the enzymatic site and valine 76 ismutated to methionine in the vascular leak site to minimize any possiblein endothelial cell damage. It is known now based on crystal structuredata that this protein is identical in structure to native ricin A chain(RTA), indicating that the point mutations contained in the molecule donot disrupt any potential tertiary structure (or potentialconformationally-dependent epitopes). When administered intramuscularly(i.m.) to mice in the absence of adjuvant, the mutant A chain elicitedantibodies that recognized ricin and animals were protected from a10×LD₅₀ dose of ricin (Smallshaw, Firan et al., 2002, A novelrecombinant vaccine which protects mice against ricin intoxication,Vaccine, 20:3422-7.).

Native PA is the dominant immunogen in AVA (anthrax vaccine adsorbed)and target for protective immunity in pre-exposure and post exposureprophylaxis as a single component vaccine. Several aluminum adsorbedrecombinant PA vaccines (2^(nd) generation), based on expression ofnative PA in avirulent B. anthracis, have been advanced and tested inrecent Phase I trials, and have been shown to be immunogenic inrelationship to AVA (Gorse, Keitel et al., 2006, Immunogenicity andtolerance of ascending doses of a recombinant protective antigen(rPA102) anthrax vaccine: a randomized, double-blinded, controlled,multicenter trial, Vaccine, 24:5950-9; Campbell, Clement et al., 2007,Safety, reactogenicity and immunogenicity of a recombinant protectiveantigen anthrax vaccine given to healthy adults, Hum Vaccin, 3:205-11).The major correlates of immunity have been well characterized in rabbitaerosol spore challenge studies (total ELISA-reactive antibodies andtoxin neutralizing activity (TNA))(Little, Ivins et al., 2004, Defininga serological correlate of protection in rabbits for a recombinantanthrax vaccine, Vaccine, 22:422-30). It is well known that anthraxtoxin is a tripartite toxin consisting of a set of three plasmid-encodedproteins expressed by B. anthracis: Protective Antigen (PA; 83 kDa),Lethal Factor (LF; 90 kDa) and Edema Factor (EF; 89 kDa). LF and EF aretransported from the extracellular surface into the cytoplasm by theheptamerized PA where they act by enzymatically modifying moleculartargets of mammalian cells. LF is a metalloprotease that cleaves andactivates several mitogen-activated protein kinases (MAPK kinases) andEF is a calmodulin-dependent adenylate cyclase that causes a rapidincrease in intracellular cAMP levels. (Young and Collier, 2007, Anthraxtoxin: receptor binding, internalization, pore formation, andtranslocation, Annu Rev Biochem, 76:243-65). These proteins are nontoxicindividually, but when administered together are a potent toxin, causingrapid cell death.

The AVA vaccine is still the only vaccine for anthrax and the major moveto improve on it is based on several perceived shortcomings: requirementfor a 6-dose regimen in order to achieve solid immunity and theperception that it is unsafe and reactogenic, and that the preparativeprocessing of AVA is crude and lacks consistency. Although PA is themajor immunogen in AVA, it is not clear whether the small amounts of LFand EF that may be present in some lots contribute to the vaccine'seffectiveness. A major factor in loss of immunogenicity of anthrax rPAinvolves accelerated deamidation on the adjuvant surface. This could beprevented by the presence of small amounts of phosphate to lower thesurface pH. There are other particular rPA vaccine candidates that arebeing developed. AVA or PA-based vaccines in general induce toxinneutralizing antibodies (Pitt, Little et al., 1999, In vitro correlateof immunity in an animal model of inhalational anthrax, J ApplMicrobiol, 87:304; Reuveny, White et al., 2001, Search for correlates ofprotective immunity conferred by anthrax vaccine, Infect Immun,69:2888-93; Little, Ivins et al., 2004, Defining a serological correlateof protection in rabbits for a recombinant anthrax vaccine, Vaccine,22:422-30). The mechanism underlying the protective action of PA-basedvaccines is attributable to anti-PA antibodies that protect the hostfrom intoxication and thus allow the immune system to deal with theorganism, though PA vaccine is not designed to limit the onset ofinfection.

There are 72 vaccines presently approved by FDA in the United States(U.S. Food and Drug Administration. Complete List of Vaccines Licensedfor Immunization and Distribution in the US. FDA. Jun. 3, 2010). Ofthese 72 vaccines, 36% contain an aluminum adjuvant and 30% are freezedried. None of the 72 vaccines contain both an aluminum adjuvant andfreeze dried component.

There is a need in the art to develop methods of producing thermostable,immunologically-active freeze dried vaccine preparations whichincorporates recombinant antigens to promote rapid onset of protectiveimmunity.

SUMMARY OF THE INVENTION

The disclosure provides a method of production of thermostable, freezedried vaccine adjuvant-containing preparations. The disclosure furtherprovides a method of production of thermostable, freeze dried vaccinepreparations in which the vaccine antigens are recombinant antigens.

In one embodiment, the disclosure provides a method of preparing animmunologically-active adjuvant-bound dried vaccine composition, themethod comprising: combining at least one aluminum-salt adjuvant, atleast one buffer system containing at least one volatile salt, at leastone glass-forming agent, at least one immunologically active co-adjuvantand at least one antigen to create a liquid vaccine formulation;freezing the liquid vaccine formulation to create a frozen vaccineformulation; and lyophilizing the frozen vaccine formulation to create adried vaccine composition, where the composition is capable of elicitingan immune response in a subject. The immune response developed by thesubject may be humoral immunity and/or cell-mediated immunity specificto the antigen. In one aspect, the at least one aluminum-salt adjuvantis selected from the group consisting of aluminum hydroxide, aluminumphosphate and aluminum sulfate. In another aspect, the aluminum-saltadjuvant is aluminum hydroxide. In a further aspect, the at least onebuffer system is selected from the group consisting of acetate,succinate, citrate, prolamine, arginine, glycine, histidine, borate,carbonate and phosphate buffer systems. In yet another aspect, the atleast one buffer system is selected from the group consisting ofammonium acetate, ammonium formate, ammonium carbonate, ammoniumbicarbonate, triethylammonium acetate, triethylammonium formate,triethylammonium carbonate, trimethylamine acetate trimethylamineformate, trimethylamine carbonate, pyridinal acetate and pyridinalformate. In another aspect, the at least one glass-forming agent isselected from the group consisting of trehalose, sucrose, ficoll,dextran, sucrose, maltotriose, lactose, mannitol, hydroxyethyl starch,glycine, cyclodextrin, and povidone. In a further aspect, theglass-forming agent is trehalose. In one aspect, the glass-forming agenttrehalose is present in a weight-to-volume concentration of from about5% to about 15% in the liquid vaccine formulation prior to freezedrying. In another aspect, the glass-forming agent trehalose is presentin a weight-to-volume concentration from about 8% to about 20% in theliquid vaccine formulation. In another embodiment, at least oneimmunologically-active co-adjuvant is added to the method steps. In thisaspect, the at least one immunologically-active co-adjuvant is selectedfrom the group consisting of lipid A, lipid A derivatives,monophosphoryl lipid A, chemical analogues of monophosphoryl Lipid A,CpG containing oligonucleotides, TLR-4 agonists, flagellin, flagellinsderived from gram negative bacteria, TLR-5 agonists, fragments offlagellins capable of binding to TLR-5 receptors, saponins, analogues ofsaponins, QS-21, purified saponin fractions, ISCOMS, saponincombinations with sterols and lipids. In a further aspect, theco-adjuvant compound is QS-21. In a further aspect, the freezing stepcomprises one of tray freezing, shelf freezing, spray-freezing andshell-freezing. In preferred embodiment, the freezing step includes useof a pre-cooled tray to initiate the freezing step.

In another aspect, the antigen is selected from or derived from thegroup consisting of rotavirus, foot and mouth disease virus, influenza Avirus, influenza B virus, influenza C virus, H1N1, H2N2, H3N2, H5N1,H7N7, H1N2, H9N2, H7N2, H7N3, H10N7, human parainfluenza type 2, herpessimplex virus, Epstein-Barr virus, varicella virus, porcine herpesvirus1, cytomegalovirus, lyssavirus, Bacillus anthracis, anthrax PA andderivatives, poliovirus, Hepatitis A, Hepatitis B, Hepatitis C,Hepatitis E, distemper virus, venezuelan equine encephalomyelitis,feline leukemia virus, reovirus, respiratory syncytial virus, Lassafever virus, polyoma tumor virus, canine parvovirus, papilloma virus,tick borne encephalitis virus, rinderpest virus, human rhinovirusspecies, Enterovirus species, Mengovirus, paramyxovirus, avianinfectious bronchitis virus, human T-cell leukemia-lymphoma virus 1,human immunodeficiency virus-1, human immunodeficiency virus-2,lymphocytic choriomeningitis virus, parvovirus B19, adenovirus, rubellavirus, yellow fever virus, dengue virus, bovine respiratory syncitialvirus, corona virus, Bordetella pertussis, Bordetella bronchiseptica,Bordetella parapertussis, Brucella abortis, Brucella melitensis,Brucella suis, Brucella ovis, Brucella species, Escherichia coli,Salmonella species, Salmonella typhi, Streptococci, Vibrio cholera,Vibrio parahaemolyticus, Shigella, Pseudomonas, tuberculosis, avium,Bacille Calmette Guerin, Mycobacterium leprae, Pneumococci,Staphlylococci, Enterobacter species, Rochalimaia henselae, Pasteurellahaemolytica, Pasteurella multocida, Chlamydia trachomatis, Chlamydiapsittaci, Lymphogranuloma venereum, Treponema pallidum, Haemophilusspecies, Mycoplasma bovigenitalium, Mycoplasma pulmonis, Mycoplasmaspecies, Borrelia burgdorferi, Legionalla pneumophila, Colstridiumbotulinum, Corynebacterium diphtheriae, Yersinia entercolitica,Rickettsia rickettsii, Rickettsia typhi, Rickettsia prowsaekii,Ehrlichia chaffeensis, Anaplasma phagocytophilum, Plasmodium falciparum,Plasmodium vivax, Plasmodium malariae, Schistosomes, trypanosomes,Leishmania species, Filarial nematodes, trichomoniasis,sarcosporidiasis, Taenia saginata, Taenia solium, Leishmania, Toxoplasmagondii, Trichinella spiralis, coccidiosis, Eimeria tenella, Cryptococcusneoformans, Candida albican, Apergillus fumigatus, coccidioidomycosis,Neisseria gonorrhoeae, malaria circumsporozoite protein, malariamerozoite protein, trypanosome surface antigen protein, pertussis,alphaviruses, adenovirus, diphtheria toxoid, tetanus toxoid,meningococcal outer membrane protein, streptococcal M protein, Influenzahemagglutinin, cancer antigen, tumor antigens, toxins, Clostridiumperfringens epsilon toxin, ricin toxin, pseudomonas exotoxin, exotoxins,neurotoxins, cytokines, cytokine receptors, monokines, monokinereceptors, plant pollens, animal dander, and dust mites.

In another embodiment, the disclosure provides a vaccine composition,comprising: at least one aluminum-salt adjuvant; at least one bufferingagent, wherein the at least one buffering agent comprises a volatilesalt; at least one glass forming agent; and at least one antigen,wherein the composition is lyophilized to create a dried vaccinecomposition and further wherein the dried vaccine composition is capableof eliciting an immune response in a subject. In one aspect, the atleast one aluminum-salt adjuvant is selected from the group consistingof aluminum hydroxide, aluminum phosphate and aluminum sulfate. Inanother aspect, the at least one buffering agent is selected from thegroup consisting of acetate, succinate, citrate, prolamine, arginine,glycine, histidine, borate, carbonate and phosphate. In an alternativeaspect, the at least one buffering agent is selected from the groupconsisting of ammonium acetate, ammonium formate, ammonium carbonate,ammonium bicarbonate, triethylammonium acetate, triethylammoniumformate, triethylammonium carbonate, trimethylamine acetatetrimethylamine formate, trimethylamine carbonate, pyridinal acetate andpyridinal formate. In yet another aspect, the at least one glass-formingagent is selected from the group consisting of trehalose, sucrose,ficoll, dextran, sucrose, maltotriose, lactose, mannitol, hydroxyethylstarch, glycine, cyclodextrin, and povidone. In a further aspect, theantigen is selected from or derived from the group consisting ofrotavirus, foot and mouth disease virus, influenza A virus, influenza Bvirus, influenza C virus, H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2,H7N2, H7N3, H10N7, human parainfluenza type 2, herpes simplex virus,Epstein-Barr virus, varicella virus, porcine herpesvirus 1,cytomegalovirus, lyssavirus, Bacillus anthracis, anthrax PA andderivatives, poliovirus, Hepatitis A, Hepatitis B, Hepatitis C,Hepatitis E, distemper virus, venezuelan equine encephalomyelitis,feline leukemia virus, reovirus, respiratory syncytial virus, Lassafever virus, polyoma tumor virus, canine parvovirus, papilloma virus,tick borne encephalitis virus, rinderpest virus, human rhinovirusspecies, Enterovirus species, Mengovirus, paramyxovirus, avianinfectious bronchitis virus, human T-cell leukemia-lymphoma virus 1,human immunodeficiency virus-1, human immunodeficiency virus-2,lymphocytic choriomeningitis virus, parvovirus B19, adenovirus, rubellavirus, yellow fever virus, dengue virus, bovine respiratory syncitialvirus, corona virus, Bordetella pertussis, Bordetella bronchiseptica,Bordetella parapertussis, Brucella abortis, Brucella melitensis,Brucella suis, Brucella ovis, Brucella species, Escherichia coli,Salmonella species, Salmonella typhi, Streptococci, Vibrio cholera,Vibrio parahaemolyticus, Shigella, Pseudomonas, tuberculosis, avium,Bacille Calmette Guerin, Mycobacterium leprae, Pneumococci,Staphlylococci, Enterobacter species, Rochalimaia henselae, Pasteurellahaemolytica, Pasteurella multocida, Chlamydia trachomatis, Chlamydiapsittaci, Lymphogranuloma venereum, Treponema pallidum, Haemophilusspecies, Mycoplasma bovigenitalium, Mycoplasma pulmonis, Mycoplasmaspecies, Borrelia burgdorferi, Legionalla pneumophila, Colstridiumbotulinum, Corynebacterium diphtheriae, Yersinia entercolitica,Rickettsia rickettsii, Rickettsia typhi, Rickettsia prowsaekii,Ehrlichia chaffeensis, Anaplasma phagocytophilum, Plasmodium falciparum,Plasmodium vivax, Plasmodium malariae, Schistosomes, trypanosomes,Leishmania species, Filarial nematodes, trichomoniasis,sarcosporidiasis, Taenia saginata, Taenia solium, Leishmania, Toxoplasmagondii, Trichinella spiralis, coccidiosis, Eimeria tenella, Cryptococcusneoformans, Candida albican, Apergillus fumigatus, coccidioidomycosis,Neisseria gonorrhoeae, malaria circumsporozoite protein, malariamerozoite protein, trypanosome surface antigen protein, pertussis,alphaviruses, adenovirus, diphtheria toxoid, tetanus toxoid,meningococcal outer membrane protein, streptococcal M protein, Influenzahemagglutinin, cancer antigen, tumor antigens, toxins, Clostridiumperfringens epsilon toxin, ricin toxin, pseudomonas exotoxin, exotoxins,neurotoxins, cytokines, cytokine receptors, monokines, monokinereceptors, plant pollens, animal dander, and dust mites.

In an alternative embodiment, the vaccine composition further includesat least one immunologically-active co-adjuvant. In one aspect, the atleast one immunologically-active co-adjuvant is selected from the groupconsisting of lipid A, lipid A derivatives, monophosphoryl lipid A,chemical analogues of monophosphoryl Lipid A, CpG containingoligonucleotides, TLR-4 agonists, flagellin, flagellins derived fromgram negative bacteria, TLR-5 agonists, fragments of flagellins capableof binding to TLR-5 receptors, saponins, analogues of saponins, QS-21,purified saponin fractions, ISCOMS and saponin combinations with sterolsand lipids.

In yet another embodiment, the disclosure provides a method ofcontrolling particle size in an adjuvant-bound dried vaccinecomposition, the method comprising: combining at least one aluminum-saltadjuvant, at least one buffer system, at least one glass-forming agent,and at least one antigen to create a liquid vaccine formulation;freezing the liquid vaccine formulation to create a frozen vaccineformulation; and lyophilizing the frozen vaccine formulation to create adried vaccine composition, wherein following dilution of the driedvaccine composition with an aqueous diluent to form a reconstitutedvaccine composition the mean particle diameter of the reconstitutedvaccine composition is less than 100 micrometers. In another aspect, theat least one aluminum-salt adjuvant is selected from the groupconsisting of aluminum hydroxide, aluminum phosphate and aluminumsulfate. In a further aspect, the aluminum-salt adjuvant is aluminumhydroxide. In another aspect, the at least one buffer system is selectedfrom the group consisting of acetate, succinate, citrate, prolamine,histidine, borate, carbonate and phosphate buffer systems. In a furtheraspect, the at least one buffer system is selected from succinate andphosphate buffer systems. In one aspect, the at least one glass-formingagent is selected from the group consisting of trehelose, sucrose,ficoll, dextran, sucrose, maltotriose, lactose, mannitol, hydroxyethylstarch, glycine, cyclodextrin, povidone, and potassium salts. In aspecific aspect, the glass-forming agent is trehalose. In a furtherspecific aspect, the glass-forming agent trehalose is present in aweight to volume concentration of from about 5% to about 20% in theliquid vaccine formulation. In another aspect, the glass-forming agenttrehalose is present in a weight to volume concentration of from about7% to about 15% in the liquid vaccine formulation. In one aspect, thefreezing step comprises one of tray freezing, shelf freezing,spray-freezing and shell-freezing. In another aspect, the freezing stepcomprises spray-freezing. In a further aspect, the mean particlediameter of the reconstituted vaccine composition is less than 6micrometers. In one aspect, the concentration of the glass forming agentin the selecting step is decreased as the rate of cooling the liquidvaccine formulation to a frozen state in the cooling step is increased.

In an alternative embodiment, the disclosure provides an adjuvantcomposition for use in a dried vaccine composition, the adjuvantcomposition comprising: an aluminum-salt adjuvant, a glass-formingagent, and a buffer salt. In one aspect, the aluminum-salt adjuvant isselected from aluminum hydroxide and aluminum phosphate. In anotheraspect, the glass-forming agent is trehalose. In a further aspect, thebuffer salt is selected from one or more of the group consisting ofsodium succinate, potassium succinate, sodium phosphate and potassiumphosphate.

In yet another embodiment, the disclosure provides an adjuvant-bounddried vaccine composition having limited mean particle diameter, thecomposition produced by a method comprising: blending at least oneadjuvant, at least one glass forming agent, and at least one antigen ina buffer system to create a liquid vaccine formulation; cooling theliquid vaccine formulation rapidly to a frozen state to create a frozenvaccine formulation; and lyophilizing the frozen vaccine formulation tocreate a dried vaccine composition, wherein following dilution of thedried vaccine composition with an aqueous diluent to form areconstituted vaccine composition, the mean particle diameter of thereconstituted vaccine composition is less than 100 micrometers.

In another embodiment, the disclosure provides a method of controllingparticle size in a frozen vaccine formulation, the method comprising:combining at least one aluminum-salt adjuvant, at least one buffersystem, at least one glass-forming agent, and at least one antigen tocreate a liquid vaccine formulation; freezing the liquid vaccineformulation to create a frozen vaccine formulation; and lyophilizing thefrozen vaccine formulation to create a dried vaccine composition,wherein following thawing and dilution of the dried vaccine compositionwith an aqueous diluent to form a reconstituted vaccine composition themean particle diameter of the reconstituted vaccine composition is lessthan 100 micrometers. In one aspect, the at least one aluminum-saltadjuvant is selected from the group consisting of aluminum hydroxide,aluminum phosphate and aluminum sulfate. In another aspect, thealuminum-salt adjuvant is aluminum hydroxide. In a further aspect, theat least one buffer system is selected from the group consisting ofacetate, succinate, citrate, prolamine, histidine, borate, carbonate andphosphate buffer systems. In one aspect, the at least one buffer systemis selected from succinate and phosphate buffer systems. In anotheraspect, the at least one glass-forming agent is selected from the groupconsisting of trehalose, sucrose, ficoll, dextran, sucrose, maltotriose,lactose, mannitol, hydroxyethyl starch, glycine, cyclodextrin, povidone,and potassium salts. In a specific aspect, the glass-forming agent istrehalose. In a further specific aspect, the glass-forming agenttrehalose is present in a weight to volume concentration of from about5% to about 20% in the liquid vaccine formulation. In another specificaspect, the glass-forming agent trehalose is present in a weight tovolume concentration of from about 7% to about 15% in the liquid vaccineformulation. In one aspect, the freezing step comprises one of trayfreezing, shelf freezing, spray-freezing and shell-freezing. In anotheraspect, the freezing step comprises spray-freezing. In a further aspect,the mean particle diameter of the reconstituted vaccine composition isless than 6 micrometers.

In another aspect, the liquid vaccine formulation is prepared as ahypertonic mixture prior to freezing, wherein upon dilution of the driedvaccine composition with an aqueous diluent to form a reconstitutedvaccine composition, the tonicity of the reconstituted vaccinecomposition is adjusted to isotonic levels. In yet another aspect, aformulation is prepared wherein the volatile salt is removed bylyophilization, yielding, upon reconstitution, a vaccine preparationwith tonicity reduced relative to the starting formulation whileretaining the same concentration of antigens and adjuvants.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts particle size distributions before and after freezedrying and reconstitutions based on % surface area.

FIG. 2 depicts particle size distributions of histidine formulationsbased on % surface area before and after freeze drying.

FIG. 3 depicts particle size distributions of arginine formulationsbased on % surface area before and after freeze drying.

FIG. 4 depicts particle size distributions of glycine formulations basedon % surface area before and after freeze drying.

FIGS. 5A-5C show Alhydrogel particles settling over time in 10 mMhistidine buffer pH 6. FIG. 5A No settling; FIG. 5B After 30 minutes ofsettling; and FIG. 5C After 3 hours of settling.

FIG. 6 depicts particle size distributions based on surface area afterallowing particles to settle for varying amounts of time before freezedrying with −10° C. pre-cooled shelves. Samples contained 1 mg/mL Al in10 mM histidine buffer at pH 6.

FIG. 7 depicts particle size distributions based on surface area afterallowing particles to settle for varying amounts of time before freezedrying with −10° C. pre-cooled shelves. Samples contained 1 mg/mL Al and8 w/v % trehalose in 10 mM histidine buffer at pH 6.

FIG. 8 shows a comparison of mean particle size between formulations of1 mg/mL Al in 10 mM histidine with and without trehalose while varyingthe settling time before freeze drying.

FIG. 9 demonstrates the steps during lyophilization in which 1 mlvaccine samples contained in 3 ml glass vials were treated to varyingfreezing rates with an FTS System LyoStar Freeze Drying System beforeprimary and secondary freezing. After freeze drying, vials were purgedwith nitrogen gas sealed and stored at −80° C. before further analysis.

FIGS. 10A-10D show particle size distributions before and after freezedrying cycles under four conditions and increasing concentrations oftrehalose. Faster rates of freezing before primary and secondary dryingand higher concentrations of trehalose result in particle sizedistributions after freeze drying are most similar to the initialparticle distribution. From slowest to fastest: room temperature tray AFIG. 10A, −10° C. Pre-cooled Tray FIG. 10B, Liquid Nitrogen dip FIG.10C, Liquid Nitrogen spray Freeze Drying FIG. 10D. Formulation consistedof 1 mg/ml as Alhydrogel, 10 mM histidine, pH 6.0, with 0-12% trehalose.

FIG. 11 shows the dependence of particle size distribution after freezedrying of room temperature freeze drying. Room temperature freeze dryingwas carried out as in FIG. 10. With room temperature incubation on traysprior to the freezing cycle, particle size distribution shifted from <1micron to >than 20 microns, and the presence of 8% trehalose reduce themagnitude of the particle size shift.

FIG. 12 shows SDS PAGE of RTA dissolved in 10 mM histidine, pH 6.0, 144mM NaCl with 50% w/v glycerol in comparison to RTA dialyzed,concentrated and stored at −20 degree C. (Top panel—silver stain, bottompanel—Coomassie stain. The same set of samples was used to perform bothstudies).

FIG. 13 shows adsorption of RTA to Alhydrogel prior to lyophilization.The concentration of RTA was varied keeping the concentration of Al at 1mg/mL. At least 95% of the RTA protein was adsorbed to the surface ofAlhydrogel at pH 6.0.

FIG. 14 shows the results of vaccination of a liquid RTA vaccineadsorbed to Alhydrogel in which various dose of RTA were used tovaccinate groups of 8 Swiss Webster mice. When the vaccine was stored at40° C. for 1 month prior to vaccination, none of the animals exposed toricin toxin survived and a significant loss of immunogenicity wasobserved. The vaccine stored at 4° C. for one month induced totalprotection at the highest doses and partial protection in mice at lowerdoses.

FIG. 15 shows rRTA antibody titers after one injection (week 3) andafter two injections (week 5) for each vaccine after no incubation, 1week and 1 month incubation at 40° C. Average titers are shown as theaverage of only the mice that responded with the standard deviation ofthose mice.

FIG. 16 shows endpoint titer data from immunized mice. EndpointTiters=reciprocal endpoint anti-RTA titers. Neutralizing IC50 Titers=thedilution of sera required to protect 50% of the cells in a well fromricin cytotoxicity Not shown here, but none of the sham immunized mice(#1-10 (except 5) had any anti-RTA titers in their sera. #1 shamimmunized mouse sera was also tested for neutralizing capacity in vitro,and did not protect cells.

FIG. 17 shows total and neutralizing titers obtained from individualsera post 2nd vaccination of Swiss Webster mice with adsorbed liquidvaccine prior to lyophilization.

DETAILED DESCRIPTION OF THE INVENTION Definitions

Trehalose dehydrate (high purity, low endotoxin) was obtained from FerroPfanstiehl (Cleveland, Ohio). Arginine, glycine, histidine, sodiumcitrate, and ammonium acetate were purchased from Sigma Chemical Company(St. Louis, Mo.). Alhydrogel™ 2.0% (aluminum hydroxide adjuvant), madeby Brenntag Biosector, was purchased through E.M. Sergeant Pulp &Chemical Co, Inc (Clifton, N.J.). 3-ml and 5-ml lyophilization vials andcaps were obtained from West Pharmaceutical Services.

Sample Preparation

Aqueous solutions were prepared containing different concentrations oftrehalose (0-15 w/v %). Unless otherwise noted, samples were prepared in10 mM buffer (as indicated) at pH 6.0 and contained 1 mg/ml Al (asAlhydrogel™). Samples were processed as one-ml aliquots. With theexception of the adjuvant, all aqueous solutions were passed through a0.2 μm filter prior to formulation.

Surface Charge Zeta Potential

Zeta potentials were measured for suspensions of aluminum hydroxide(Alhydrogel) in various formulations to probe electrostaticinteractions. Formulations without antigen were then prepared todetermine if aggregation of particles occurred during freeze drying.Alhydrogel at a concentration of 1 mg Al/mL was combined in 10 mM buffer(glycine, arginine, histidine, ammonium acetate, sodium citrate) at pH 6with the stabilizer trehalose ranging from 0-12 w/v %. To determine ifthe rate of freezing affects particle aggregation, formulations werefreeze dried using four methods of freezing: Room Temperature TrayFreezing, −10° C. Pre-cooled Tray Freezing, Liquid Nitrogen DipFreezing, and Liquid Nitrogen Spray Freezing before primary andsecondary drying. Protein was also added to formulations to see itseffect on particle size after freeze drying and reconstitution. Particlesize distributions in the range of 0.04-2000 μm were characterized bylaser diffraction for each formulation.

Lyophilization

An FTS Systems Lyostar lyophilizer was used for the freeze-drying ofsamples. Samples were frozen at various cooling rates as follows fromslowest to fastest: (i) Vials prepared at room temperature were placedon the lyophilizer trays and kept at room temperature for 1 hour priorto initiating the (ii.) Frozen by placing the samples in lyophilizer,equilibrating 1 hr at a shelf temperature of −10° C., then cooling theshelves at 0.5° C./min to −40° C. (“−10 pre-cooled tray-freezing”);(ii.) Frozen by immersion of bottom of vial into liquid N₂ (LN2 DipFreeze Drying); and (iii.) Spray-freezing by dropping by ˜20 μl dropletsinto liquid N₂. (LN2 spray freeze drying). Tray-frozen and liquidN₂-immersed samples were processed in 3-ml lyophilization vials, whilethe spray-frozen samples were processed in 5-ml lyophilization vials.Vials containing samples frozen using liquid N₂ were quickly transferredto the lyophilizer placed on lyophilizer shelves pre-cooled to −40° C.Samples were spaced in the lyophilizer so that they were each separatedfrom one another and were encircled with a row of vials containingwater.

Primary drying of the samples was achieved by setting the shelftemperature to −20° C. and applying vacuum at 60 mTorr for 20 hours, andwas followed by secondary drying, in which shelf temperatures wereramped from −20° C. to 0° C. at 0.2° C./min, to 30° C. at 0.5° C./minand finally held at 30° C. for 5 hours. Samples were sealed under vacuumand reconstituted with DI water prior to analysis. The variations of thefreezing and drying cycles are depicted in (FIG. 10).

Particle Size Distributions

Particle size distributions (PSD) were measured using a Beckman-CoulterLS230 laser diffraction particle size analyzer. Three one-ml sampleswere required for each run, and three replicates of each run werecompleted per formulation. Reported PSD's are surface area weighted andare composites of three runs.

Examples

I. −10° C. Pre-Cooled Tray Freeze Drying with Varying Settling Time ofParticles

10 mM histidine buffer at pH 6.0, 1 mg/mL Al from Alhydrogel, and 0, 4,8 or 12 w/v % trehalose was combined and rotated end over end for 30minutes at 4° C. 1 mL of the solution was placed in each 3 mL glassfreeze drying vial. The formulations were placed on −10° C. pre-cooledshelves in the freeze drier and freeze dried as follows in the tablebelow. Following freeze drying, the chamber was backfilled with drynitrogen gas and the vials were sealed.

TABLE 1 Initial Final Temp Temp Stage Time for Step (° C.) (° C.)Pressure Rate Freezing 0.25 hours −10 −10 Atmospheric Constant temp −101 hours −10 −40 Atmospheric −0.5° C./min 1 hour −40 −40 AtmosphericConstant temp −40 Primary 0.5 hours −40 −40 60 mTorr Constant Dryingtemp −40 0.5 hour −40 −20 60 mTorr Increase temp 20 hours −20 −20 60mTorr Constant temp −20 Secondary 1 hour 40 min −20 0 60 mTorr 0.2°C./min Drying 1 hour 0 30 60 mTorr 0.5° C./min 5 hours 30 30 60 mTorrConstant temp 30

Particle Size Analysis

Particle size analysis was done on the solutions before they were freezedried as well as on the freeze dried samples reconstituted in 1 mL of DIwater. Laser diffraction particle size analysis was done using a LS 230instrument made by Beckman. For the analysis no sonication was done onthe sample chamber. The model used for calculating particle sizedistributions used a solution refractive index of 1.33 and a samplerefractive index of 1.57. Approximately 6 mL of sample was required tobe added to filtered DI water in the analyzer before the reading wastaken. For each run three ninety second averaged particle sizedistributions were taken. For each formulation three runs were taken.

Results

When formulations contained higher concentrations of trehalose (8-12 w/v%) the initial particle size distribution was able to be maintained asseen in FIG. 1.

II. −10° C. Pre-Cooled Tray Freeze Drying

10 mM buffer, 1 mg/mL Al from alhydrogel, 10 w/v % trehalose with andwithout 0.26 mg/mL rRTA was combined and rotated end over end for 30minutes at 4° C. 1 mL of the solution was placed in each 3 mL glassfreeze drying vial. The formulations were placed on −10° C. pre-cooledshelves in the freeze drier and freeze dried as follows in the tablebelow. Following freeze drying, the chamber was backfilled with drynitrogen gas and the vials were sealed.

TABLE 2 Initial Final Temp Temp Stage Time for Step (° C.) (° C.)Pressure Rate Freezing 0.25 hours −10 −10 Atmospheric Const. temp 5 1hours −10 −40 Atmospheric −0.5° C./min 1 hour −40 −40 Atmospheric Const.temp −40 Primary 0.5 hours −40 −40 60 mTorr Const. Drying temp −40 0.5hour −40 −20 60 mTorr Increase temp 20 hours −20 −20 60 mTorr Const.temp −20 Secondary 1 hour 40 min −20 0 60 mTorr 0.2° C./min Drying 1hour 0 30 60 mTorr 0.5° C./min 5 hours 30 30 60 mTorr Const. temp 30

Particle Size Analysis

Particle size analysis was done on the solutions before they were freezedried as well as on the freeze dried samples reconstituted in 1 mL of DIwater. Laser diffraction particle size analysis was done using a LS 230instrument made by Beckman. For the analysis no sonication was done onthe sample chamber. The model used for calculating particle sizedistributions used a solution refractive index of 1.33 and a samplerefractive index of 1.57. Approximately 6-7 mL of sample was required tobe added to filtered DI water in the analyzer before the reading wastaken. For each run three ninety second averaged particle sizedistributions were taken. For each formulation three runs were taken.

Results

In arginine, histidine, and glycine buffers containing 10 w/v %trehalose, both with and without rRTA protein present, the particle sizedistribution was able to be maintained before freeze drying and afterusing −10° C. pre-cooled shelves before freeze drying. Particle sizedistributions can be seen in FIGS. 1-3. Particle size distributionscould possibly be maintain better with pre-cooled shelves before freezedrying than tray freeze drying because the adjuvant particles have lesstime to settle before the formulation freezes when pre-cooled shelvesare used.

III. −10° C. Pre-Cooled Tray Freeze Drying with Varying Settling Time ofParticles at 3 Hour, 30 Minute and 0 Timepoints Before Freeze Drying

10 mM histidine buffer at pH 6, 1 mg/mL Al from alhydrogel, and 0 or 8w/v % trehalose was combined and rotated end over end for 30 minutes at4° C. 1 mL of the solution was placed in each 3 mL glass freeze dryingvial. The vials were divided into three groups that were allowed to restfor 3 hours, 30 minutes and 0 minutes before being placed in the freezedrier. Once vials were filled they were allowed to sit at 4° C. until itwas time to be loaded in the freeze drier. The formulations were placedon −10° C. pre-cooled shelves in the freeze drier and freeze dried asfollows in the table below. Following freeze drying, the chamber wasbackfilled with dry nitrogen gas and the vials were sealed.

TABLE 3 Initial Final Temp Temp Stage Time for Step (° C.) (° C.)Pressure Rate Freezing 0.25 hours −10 −10 Atmospheric Constant temp 5 1hours −10 −40 Atmospheric −0.5° C./min 1 hour −40 −40 AtmosphericConstant temp −40 Primary 0.5 hours −40 −40 60 mTorr Constant Dryingtemp −40 0.5 hour −40 −20 60 mTorr Increase temp 20 hours −20 −20 60mTorr Constant temp −20 Secondary 1 hour 40 min −20 0 60 mTorr 0.2°C./min Drying 1 hour 0 30 60 mTorr 0.5° C./min 5 hours 30 30 60 mTorrConstant temp 30

Particle Size Analysis

Particle size analysis was done on the solutions before they were freezedried as well as on the freeze dried samples reconstituted in 1 mL of DIwater. Laser diffraction particle size analysis was done using a LS 230instrument made by Beckman. For the analysis no sonication was done onthe sample chamber. The model used for calculating particle sizedistributions used a solution refractive index of 1.33 and a samplerefractive index of 1.57. Approximately 6 mL of sample was required tobe added to filtered DI water in the analyzer before the reading wastaken. For each run three ninety second averaged particle sizedistributions were taken. For each formulation two runs were taken.

Results

Before samples were placed in the freeze drier they were allowed tosettle for 0 minutes, 30 minutes or 3 hours. In FIGS. 5A-5C, a vialcontaining 1 mg/mL Al from Alhydrogel in 10 mM histidine is shown atvarious time points during settling. Without settling, the formulationappears to be cloudy throughout the solution (FIG. 5A). After 30 minutesof settling the majority of the alhydrogel particles appear to be closeto the bottom of the vial with a slightly cloudy solution above (FIG.5B). After 3 hours of settling the alhydrogel particles have settledcloser to the bottom of the vial and leave a clear solution above thealhydrogel layer (FIG. 5C).

When the formulation contained alhydrogel and histidine withouttrehalose, the particle size distribution was shifted towards largerparticles from the initial particle size distribution (FIG. 6).Formulations that were allowed to settle for less time produced slightlysmaller particles than those allowed to settle for longer periods oftime.

When formulations contained 8 w/v % trehalose, the amount of time thesamples were allowed to settle before being placed in the freeze driereffected the particle size distribution (FIG. 7). When the formulationwas not allowed to settle before being placed in the freeze drier, theparticle size distribution was very similar to the initial particle sizedistribution before freeze drying. After 30 minutes of settling theparticle size distribution starts to shift to larger particle sizes andat 3 hours of settling the particles are significantly larger than theinitial particle size distribution.

When comparing the formulations with trehalose in comparison the oneswithout trehalose, trehalose presence in the formulation in maintainsthe particle size distribution after the freeze drying process. Althoughthe initial mean particle size before freeze drying is the same with andwithout trehalose present in the formulation, the mean particle sizeafter freeze drying is smaller when trehalose is present in theformulation at each amount of settling before freeze drying as can beseen in FIG. 8. From these experiments we can also see the importance ofnot allowing the samples to settle before loading in the freeze drier ifit is desired to maintain the initial particle size.

IV. Immunogenicity of Ricin Vaccine Subunit in Experimental Animals.

As an example, a thermostable lyophilized ricin subunit vaccine wasconstructed and tested. Ricin A chain vaccine was used because it issubject to aggregation and denaturation in aqueous buffers and is proneto losses in structural integrity that affect immunogenicity and theinduction of neutralizing antibodies involved in protection againstricin toxin exposure. A lyophilized ricin vaccine was prepared asfollows. RTA dissolved in glycerol was dialyzed against 10 mM histidinebuffer, pH 6.0 to remove glycerol (FIG. 11). The liquid suspensionvaccine was placed into vials and subjected to lyophilization asdescribed in FIGS. 10A-10D to compare precooled freeze drying at −10degrees C. with vaccine at room temperature prior to initiating of theprimary freeze drying cycle at −40° C. The dried vaccines were storedeither at refrigeration temperature (4-8° C.) or at elevated temperature(40-60° C.). Samples from the stored lyophilized vaccine were withdrawnperiodically and tested for structural integrity by assessment ofbinding of a diagnostic monoclonal antibody termed R70 (Neal, O'Hara etal., 2010, A monoclonal immunoglobulin G antibody directed against animmunodominant linear epitope on the ricin A chain confers systemic andmucosal immunity to ricin, Infect Immun, 78:552-61). In addition,vaccines were subjected to additional biophysical tests including thedetermination of intrinsic fluorescence diagnostic of tertiary structureof protein bound to aluminum, determination of residual water, andimmunogenicity/potency in mice. Immunogenicity was determined byinjecting Swiss Webster mice as below and determining total antibodiesagainst the vaccine by ELISA and determination of ricin neutralizingantibodies. Mice were exposed to ricin toxin at day 35 by injection of10×LD50 dose of toxin and lethality was determined in the exposedanimals. In addition, peptide scans were performed in which serum fromvaccinated and control mice were assessed for response to overlappingpeptides encompassing the RTA molecule. This was done to determine theimmunodominant regions and their preservation during high and lowtemperature storage conditions. When control liquid vaccine was used tovaccinate mice 3× by intramuscular injection, incubation of the vaccineat 40° C. for one month resulted in loss of immunogenicity and theability to induce protective immunity (FIG. 14).

During the study, each Swiss Webster mouse was bled three times andinjected with a vaccine formulation twice. Before the initial injectionmice were bled and then on day 0 injected with a vaccine formulation.The initial bleeding was necessary so that each mouse could be its ownbaseline. 21 days later the mice were bled and injected with a boostervaccine formulation. 35 days after the initial injection the mice werebled one last time. Before bleeding procedures the mice wereanesthetized using is isofluorane inhalant. Blood was drawn from theretro-orbital venous sinus of the mice. A drop of proparacaine was puton the eye from which blood was drawn and then blood was collected using504, capillary tubes. Approximately 100-2004, of blood was drawn duringeach bleeding.

TABLE 4 Group Contents Negative Control Freeze dried Alhydrogel inhistidine buffer Negative Control Freeze dried Alhydrogel in ammoniumacetate buffer Positive Control Liquid formulation of rRTA andAlhydrogel Experimental Group 1 Freeze dried (Room temp shelves) rRTAand Alhydrogel in histidine buffer Experimental Group 2 Freeze dried(Room temp shelves) rRTA and Alhydrogel in ammonium acetate bufferExperimental Group 3 Freeze dried (Pre-cooled shelves) rRTA andAlhydrogel in histidine buffer Experimental Group 4 Freeze dried(Pre-cooled shelves) rRTA and Alhydrogel in ammonium acetate buffer

To create variations in the formulation particle size, different bufferssuch as histidine and ammonium acetate and the variation of freezingrate before freeze drying (such as room temperature shelves orpre-cooled shelves before freeze drying) were used. All samplescontained the disaccharide trehalose up to 15% (w/V) and Alhydrogel isan aluminum hydroxide vaccine adjuvant used at 0.85-1 mg/ml totalaluminum.

V. Controlled Lyophilization of Adsorbed Ricin Vaccine.

The central objective of this invention is to make subunit vaccines byemploying controlled lyophilization of protein, aluminum adjuvant, andimmunostimulant components for reconstitution with water at the point ofuse. Using aluminum adjuvant, it has not been feasible or possible up tothis point to adequately combine these components together without lossof vaccine effectiveness on the one hand and gross clumping andinability to rehydrate adequately. A number of different conditions forprecisely controlling points in the lyophilization cycle examining aspectrum of buffer conditions, salt conditions, and lyophilization cycleconditions and have reported that we had been able to define conditionsfor retaining gross integrity including protein structure pre and postlyophilization.

VI. Generation of Prototype Freeze Dried Vaccines.

A series of freeze dried formulation was made according to the generallyophilization schemes presented in Table 1. Freeze dried formulationswith RTA protein and placebo formulations without protein were createdcontaining 1.0 mg Al/mL, 8 w/v % trehalose and 0.2 or 0 mg/mL rRTA in 10mM histidine or ammonium acetate buffer pH 6, with either pre-cooling(PC) prior to lyophilization or room temperature incubation prior tolyophilization. Formulations were prepared by mixing with a stir bar at4-8° C. for 1 hour to allow protein to adsorb to Alhydrogel adjuvant. 1mL of formulation was placed in a 3 mL glass vial and freeze dried asdescribed in Table 4. Samples from each process condition were incubatedat 40° C. and withdrawn for analysis and vaccination studies at 1 week,one month (and continuing through month 6). Pre- and post-lyophilizationsamples were also obtained.

TABLE 5 Freeze Drying Cycle Initial Final Temp Temp Stage Time for Step(° C.) (° C.) Pressure Rate −10° C. 0.25 hour −10 −10 AtmosphericConstant Pre- temp −10 Cooled Tray Freezing 1 hour −10 −40 Atmospheric−0.5° C./min 1 hour −40 −40 Atmospheric Constant temp −40 Primary 0.5hours −40 −40 60 mTorr Constant Drying temp −40 0.5 hour −40 −20 60mTorr Increase temp 20 hours −20 −20 60 mTorr Constant temp −20Secondary 1 hour 40 min −20 0 60 mTorr 0.2° C./min Drying 1 hour 0 30 60mTorr 0.5° C./min 5 hours 30 30 60 mTorr Constant temp 30

VII. Particle Size Analysis of Reconstituted Dried Vaccines.

Particle size analysis was done on the solutions before they were freezedried as well as on the freeze dried samples reconstituted in 1 mL ofdeionized water. Laser diffraction particle size analysis was conductedusing a LS 230 instrument made by Beckman. For the analysis nosonication was done on the sample chamber. The model used forcalculating particle size distributions used a solution refractive indexof 1.33 and a sample refractive index of 1.57. Approximately 6 mL ofsample was required to be added to filtered DI water in the analyzerbefore the reading was taken. For each run three ninety second averagedparticle size distributions were taken. For each formulation three runswere taken. The particle size distribution of the placebo stabilitystudy samples is being monitored over with using laser diffraction. Theinitial Time 0 liquid formulations all had similar particle sizedistributions and mean particle sizes based on surface area as can beseen in Table 5. When formulations were Tray Freeze Dried from RoomTemperature, an increase in particle size was seen. When formulationswere Tray Freeze Dried from −10° C. Pre-Cooled Shelves, the particlesize distribution stayed very similar to the initial particle sizedistribution.

TABLE 6 Mean particle size ± standard deviation based on surface areaVaccine Time Point RT His RT AA PC His PC AA Time 0 -  0.35 ± 0.01 0.34± 0.01 0.35 ± 0.01 0.35 ± 0.01 Liquid Time 0 -  9.43 ± 0.31 8.11 ± 0.740.38 ± 0.06 0.49 ± 0.05 FD Time 1 10.69 ± 0.41 8.96 ± 0.16 0.44 ± 0.090.42 ± 0.05 Week - FD Time 1 10.31 ± 0.63 9.09 ± 0.12 0.46 ± 0.12 0.55 ±0.07 Month - FD

VIII. Vaccination of Animals.

Female Swiss Webster mice 5-6 weeks old were vaccinated with 50 μL ofthe indicated formulations containing 10 microgram of RTA proteinsubcutaneously on Day 0 and 20. Mice under anesthesia by isoflurane werebled through the retro orbital cavity collecting approximately 2004, ofblood on Day 0, 20 and 34. In each group 10 mice were used. Mice werehoused 5 per cage and were allowed food and water all the time. Serumwas separated from blood by centrifugation at 10,000 rpm for 14 minutesat 4° C.

Total antibody to RTA in individual sera from vaccinated Swiss Webstermice was determined by ELISA and for determination of neutralizingantibodies (FIGS. 6 and 7). Nunc flat bottom MaxiSorb 96 well plateswere coated with 50 μL/well of stock protein diluted in PBS to 1 μgrRTA/mL and incubated at 2-6° C. overnight. Plates were washed 4 timeswith 300 μL/well of PBS with 0.05% Tween 20. Plates were blocked with300 μL/well of PBS with 1% BSA and incubated at room temperature for 2hours. Plates were washed as previously described. 40 μL of PBS with 1%BSA and 0.05% Tween 20 was added to each well. Serum was initiallydiluted in a dilution buffer of PBS with 1% BSA and 0.05% Tween 20. 70μL of sample was added to the starting well and then a seven in-plate2.33-fold dilution was created for each sample. The plate was thenincubated for 2 hours at room temperature. Plates were washed again. 40μL of HRP-conjugated donkey anti-mouse antibody diluted 10,000 times wasadded to each well and incubated for 2 hours at room temperature. Plateswere washed again. TMB was added to each well at 40 μL and incubated for30 minutes. Stop solution of 2N sulfuric acid was added at 40 to eachwell. The plate was read at 450 nm. Endpoint dilution analysis ofindividual serum samples from vaccinated mice is shown in FIG. 15. Thevaccines tested are abbreviated as follows:

RT His—Negative control (room temperature tray freeze dried in histidinewith no protein)RT AA—Negative control (room temperature tray freeze dried in ammoniumacetate with no protein)His+rRTA Liquid—Positive control (liquid formulation in histidine withprotein)RT His+rRTA—Experimental 1 (room temperature tray freeze dried inhistidine with protein)RT AA+rRTA—Experimental 2 (room temperature tray freeze dried inammonium acetate with protein)RPC His+rRTA—Experimental 3 (Pre-Cooled tray freeze dried in histidinewith protein)PC AA+rRTA—Experimental 4 (Pre-Cooled tray freeze dried in ammoniumacetate with protein)

When vaccines were stored for one or one month at 40° C., there was nosignificant difference in the capacity of the vaccines to generateantibodies against RTA (by ELISA) after one injection of 10 microgram(week 3 titers) or 2 injections (week 5) in relationship to vaccineprepared without storage at 40° C. (time 0 in FIG. 15). At week three,90-100% of mice in each experimental and positive control groupresponded and by week five all experimental and positive controlresponded (Table 3). More important, serum obtained from post 2 (week 5)contained antibodies that neutralized ricin (in vitro) where the titersand the proportion of mice with such titers were not obviously differentfrom time 0 vaccines (FIG. 16) or the liquid vaccines (FIG. 17).Further, neutralizing titers decreased after storage of lyophilized RTAvaccine at 40° C. for 1 month, in sera from mice that were given vaccineplaced on a room temperature tray before freeze drying. In contrast,vaccines made by precooling prior to freeze drying had better total andneutralizing anti-RTA titers than those immunized with liquid vaccine.

TABLE 7 Number of mice responding to the vaccine after week 3 and week 5# of with Antibody Titer Vaccine Week 3 Week 5 Positive Control -  9/1010/10 Liquid His + rRTA Time 0 - RT His + rRTA 10/10 10/10 Time 0 - RTAA + rRTA 10/10 10/10 Time 0 - PC His + rRTA  9/10 10/10 Time 0 - PCAA + rRTA 10/10 10/10 Time 1 Week - RT His + rRTA 10/10 10/10 Time 1Week - RT AA + rRTA 9/9 10/10 Time 1 Week - PC His + rRTA 10/10 10/10Time 1 Week - PC AA + rRTA  9/10 10/10 Time 1 Month - RT His + rRTA 9/10 10/10 Time 1 Month - RT AA + rRTA 10/10 10/10 Time 1 Month - PCHis + rRTA 10/10 10/10 Time 1 Month - PC AA + rRTA 10/10 10/10IX. Vaccination of Animals with Vaccines Containing SecondaryCo-Adjuvants.

A series of freeze dried formulation was made according to the generallyophilization schemes presented in Table 1. Freeze dried formulationswith RTA protein and placebo formulations without protein were createdcontaining 1.0 mg Al/mL, 8 w/v % trehalose and 0.2 or 0 mg/mL rRTA and60 micrograms of TLR-4 agonist, a synthetic derivative of monophosphorylLipid A (MPL) termed PHAD, obtained from Avanti Polar Lipids (Alabaster,Ala.). Vaccines were made in several different manners. In method (1),RTA protein was adsorbed (bound) to aluminum hydroxide in 10 mMhistidine or ammonium acetate buffer pH 6 in the presence of 8%trehalose, followed by addition of PHAD agonist to the aqueoussuspension. For this method, RTA stored in stabilizer buffer consistingof 10 mM histidine, pH6.0, and 144 mM NaCl, was subjected to dialysisinto glycerol- and salt-free buffer prior to adsorption to aluminumadjuvant. In method (2), RTA stored in stabilizing glycerol buffer wasdiluted 10 fold in 10 mM histidine, pH 6.0, 144 mM NaCl prior to theaddition of aluminum to the diluted stabilizing buffer. For this methodadsorption was allowed to occur at 4 C° for more than 5 hours so thatgreater than 95% of the RTA became bound to aluminum gel particles.Subsequently, the aluminum particles were allowed to settle to thebottom of the adsorption vessel or the mixture was subjected tocentrifugation to separate the particles from the aqueous buffer. Tothis Aluminum mixture was added a buffer system (ammonium acetate orhistidine) containing 8% trehalose. In this manner the isotonicity ofthe system could be maintained. For method 1 and method 2, subsequentlyophilization proceeded with either pre-cooling (PC) prior tolyophilization or room temperature incubation prior to lyophilization.

Samples from each process condition were incubated at 4° C. and 40° C.and withdrawn for analysis and vaccination studies at 1 week, one month,2 months, 3 months, 6 months, 9 months, 12 months, 18 months, and 24months. For potency analysis, Swiss Webster mice were vaccinated with aconcentration range that kept the adjuvant components (aluminum andPHAD) constant while varying the dose of RTA immunogen. For controlstudies, mice were vaccinated with vaccine that did not containco-adjuvant PHAD, using the same dose range as the PHAD containinglyophilized vaccines. Two vaccination protocols were used.

One set of mice were vaccinated with one dose of vaccine on study day 1,and another set of mice was vaccinated with vaccine on study days 1 and21. Serum was obtained from animals at the time of each vaccination andtwo weeks thereafter. For final analysis, mice were exposed to 10×LD 50of ricin toxin on day 35 and survivors were recorded. The animals thatwere vaccinated with the PHAD-containing dried reconstituted vaccinesamples demonstrated a significant shift of the dose response curvetoward lower doses of RTA immunogen for the serological endpoints (totalRTA reactive antibodies and ricin neutralizing antibodies) and alsodemonstrated protective immunity at the lower dose range when subjectedto ricin exposure in comparison to the vaccine without the co-adjuvant.Equally significant, the vaccine samples that were incubated at thehigher temperature also demonstrated enhanced immune response,indicating that all of the components of the vaccine were stabilized.Furthermore, the PHAD vaccines induced a broader immune responsereflected by a higher titer of neutralizing antibodies and broaderresponse to neutralizing epitopes.

X. Glass Transition Temperature.

Glass transition temperature (Tg) is an indicator of stability of thevaccine product. Below or near the Tg the vaccine behaves as a glass andall components of the vaccines are stabilized within the glass. Abovethe Tg, the sample becomes is less stable, and the components within thematrix also become less stable. The Tg is measured by differentialscanning calorimetry in the following manner. The Tg of the sample isdetermined by subjecting the sample to a controlled temperature programfrom 0° C. to 150° C. at a rate of 10° C./min. The heat flow to and fromthe sample is measured and expressed as a shift in the baseline. The Tgis expressed as the temperature at the midpoint of this baseline shift.

Lyophilized RTA vaccines subjected to DSC analysis demonstrate a highglass transition temperature in excess of 100° C. and lower than 0.5%water content (Karl Fischer analysis).

As used in this specification and in the appended claims, the singularforms include the plural forms. For example the terms “a,” “an,” and“the” include plural references unless the content clearly dictatesotherwise. Additionally, the term “at least” preceding a series ofelements is to be understood as referring to every element in theseries. The inventions illustratively described herein can suitably bepracticed in the absence of any element or elements, limitation orlimitations, not specifically disclosed herein. Thus, for example, theterms “comprising,” “including,” “containing,” etc. shall be readexpansively and without limitation. Additionally, the terms andexpressions employed herein have been used as terms of description andnot of limitation, and there is no intention in the use of such termsand expressions of excluding any equivalents of the future shown anddescribed or any portion thereof, and it is recognized that variousmodifications are possible within the scope of the invention claimed.Thus, it should be understood that although the present invention hasbeen specifically disclosed by preferred embodiments and optionalfeatures, modification and variation of the inventions herein disclosedcan be resorted by those skilled in the art, and that such modificationsand variations are considered to be within the scope of the inventionsdisclosed herein. The inventions have been described broadly andgenerically herein. Each of the narrower species and subgenericgroupings falling within the scope of the generic disclosure also formpart of these inventions. This includes the generic description of eachinvention with a proviso or negative limitation removing any subjectmatter from the genus, regardless of whether or not the excisedmaterials specifically resided therein. In addition, where features oraspects of an invention are described in terms of the Markush group,those schooled in the art will recognize that the invention is alsothereby described in terms of any individual member or subgroup ofmembers of the Markush group. It is also to be understood that the abovedescription is intended to be illustrative and not restrictive. Manyembodiments will be apparent to those of in the art upon reviewing theabove description. The scope of the invention should therefore, bedetermined not with reference to the above description, but shouldinstead be determined with reference to the appended claims, along withthe full scope of equivalents to which such claims are entitled. Thoseskilled in the art will recognize, or will be able to ascertain using nomore than routine experimentation, many equivalents to the specificembodiments of the invention described. Such equivalents are intended tobe encompassed by the following claims.

What is claimed is:
 1. A method of preparing a composition, the methodcomprising: (a) providing at least one aluminum-salt adjuvant; at leastone buffering agent selected from the group consisting of acetate,succinate, citrate, prolamine, arginine, glycine, histidine, borate,carbonate and phosphate and at least one volatile salt, the volatilesalt selected from the group consisting of ammonium acetate, ammoniumformate, ammonium carbonate, ammonium bicarbonate, triethylammoniumacetate, triethylammonium formate, triethylammonium carbonate,trimethylamine acetate trimethylamine formate, trimethylamine carbonate,pyridinal acetate and pyridinal formate; at least one glass-formingagent and at least one antigen; (b) combining (a) together to create aliquid formulation; (c) cooling the liquid formulation to below afreezing state in (b) to create a frozen formulation; and (d)lyophilizing the frozen formulation in (c) to create a driedcomposition.
 2. The method of claim 1, wherein the at least onealuminum-salt adjuvant is selected from the group consisting of aluminumhydroxide, aluminum phosphate and aluminum sulfate.
 3. The method ofclaim 1, wherein the buffering agent is selected from the groupconsisting of citrate, glycine, histidine, and phosphate.
 4. The methodof claim 1, wherein the at least one volatile salt is selected from thegroup consisting of ammonium acetate, ammonium formate, and ammoniumcarbonate.
 5. The method of claim 1, wherein the at least oneglass-forming agent is selected from the group consisting of trehalose,sucrose, hydroxyethyl starch, ficoll, dextran, maltotriose, lactose,mannitol and glycine, cyclodextrin and povidone.
 6. The method of claim1, wherein the at least one glass-forming agent is trehalose.
 7. Themethod of claim 1, wherein the at least one glass-forming agent istrehalose and the trehalose is present in a weight-to-volumeconcentration of from about 8% to about 20% in the liquid vaccineformulation.
 8. The method of claim 1, wherein at least oneimmunologically-active co-adjuvant is added in (a).
 9. The method ofclaim 8, wherein the at least one immunologically-active co-adjuvant isselected from the group consisting of lipid A, lipid A derivatives,monophosphoryl lipid A, chemical analogues of monophosphoryl Lipid A,CpG containing oligonucleotides, TLR-4 agonists, flagellin, flagellinsderived from gram negative bacteria, TLR-5 agonists, fragments offlagellins capable of binding to TLR-5 receptors, saponins, analogues ofsaponins, QS-21, purified saponin fractions, ISCOMS and saponincombinations with sterols and lipids.
 10. The method of claim 1, whereinthe freezing step comprises one of tray freezing, shelf freezing,dip-freezing, spray-freezing and shell-freezing.
 11. The method of claim1, wherein the freezing step includes use of a pre-cooled tray orspray-freezing to initiate the freezing step.
 12. The method of claim 1,wherein the antigen is selected from or derived from the groupconsisting of rotavirus, foot and mouth disease virus, influenza Avirus, influenza B virus, influenza C virus, H1N1, H2N2, H3N2, H5N1,H7N7, H1N2, H9N2, H7N2, H7N3, H1ON7, human parainfluenza type 2, herpessimplex virus, Epstein-Barr virus, varicella virus, porcine herpesvirus1, cytomegalovirus, lyssavirus, Bacillus anthracis, anthrax PA andderivatives, poliovirus, Hepatitis A, Hepatitis B, Hepatitis C,Hepatitis E, distemper virus, Venezuelan equine encephalomyelitis,feline leukemia virus, reovirus, respiratory syncytial virus, Lassafever virus, polyoma tumor virus, canine parvovirus, papilloma virus,tick borne encephalitis virus, rinderpest virus, human rhinovirusspecies, Enterovirus species, Mengovirus, paramyxovirus, avianinfectious bronchitis virus, human T-cell leukemia-lymphoma virus 1,human immunodeficiency virus-1, human immunodeficiency virus-2,lymphocytic choriomeningitis virus, parvovirus B19, adenovirus, rubellavirus, yellow fever virus, dengue virus, bovine respiratory syncitialvirus, corona virus, Bordetella pertussis, Bordetella bronchiseptica,Bordetella parapertussis, Brucella abortis, Brucella melitensis,Brucella suis, Brucella ovis, Brucella species, Escherichia coli,Salmonella species, Salmonella typhi, Streptococci, Vibrio cholera,Vibrio parahaemolyticus, Shigella, Pseudomonas, tuberculosis, avium,Bacille Calmette Guerin, Mycobacterium leprae, Pneumococci,Staphlylococci, Enterobacter species, Rochalimaia henselae, Pasteurellahaemolytica, Pasteurella multocida, Chlamydia trachomatis, Chlamydiapsittaci, Lymphogranuloma venereum, Treponema pallidum, Haemophilusspecies, Mycoplasma bovigenitalium, Mycoplasma pulmonis, Mycoplasmaspecies, Borrelia burgdorferi, Legionalla pneumophila, Colstridiumbotulinum, Corynebacterium diphtheriae, Yersinia entercolitica,Rickettsia rickettsii, Rickettsia typhi, Rickettsia prowsaekii,Ehrlichia chaffeensis, Anaplasma phagocytophilum, Plasmodium falciparum,Plasmodium vivax, Plasmodium malariae, Schistosomes, trypanosomes,Leishmania species, Filarial nematodes, trichomoniasis,sarcosporidiasis, Taenia saginata, Taenia solium, Leishmania, Toxoplasmagondii, Trichinella spiralis, coccidiosis, Eimeria tenella, Cryptococcusneoformans, Candida albican, Apergillus fumigatus, coccidioidomycosis,Neisseria gonorrhoeae, malaria circumsporozoite protein, malariamerozoite protein, trypanosome surface antigen protein, pertussis,alphaviruses, adenovirus, diphtheria toxoid, tetanus toxoid,meningococcal outer membrane protein, streptococcal M protein, Influenzahemagglutinin, cancer antigen, tumor antigens, toxins, Clostridiumperfringens epsilon toxin, ricin toxin, pseudomonas exotoxin, exotoxins,neurotoxins, cytokines, cytokine receptors, monokines, monokinereceptors, plant pollens, animal dander, and dust mites. 13-14.(canceled)
 15. The method of claim 1, wherein the liquid formulation isfirst prepared as a hypertonic mixture prior to freezing and thenadjusted to isotonic levels upon dilution of the dried composition withan aqueous diluent.
 16. A vaccine composition, comprising: (a) at leastone aluminum-salt adjuvant; (b) at least one buffering agent selectedfrom the group consisting of acetate, succinate, citrate, prolamine,arginine, glycine, histidine, borate, carbonate and phosphate and atleast one volatile salt, the volatile salt is selected from the groupconsisting of ammonium acetate, ammonium formate, ammonium carbonate,ammonium bicarbonate, triethylammonium acetate, triethylammoniumformate, triethylammonium carbonate, trimethylamine acetatetrimethylamine formate, trimethylamine carbonate, pyridinal acetate andpyridinal formate; (c) at least one glass forming agent; (d) at leastone immunologically-active co-adjuvant; and (e) at least one antigen,wherein the composition is lyophilized to create a dried vaccinecomposition and further wherein the dried vaccine composition is capableof eliciting an immune response in a subject.
 17. The vaccinecomposition of claim 16, wherein the at least one aluminum-salt adjuvantis selected from the group consisting of aluminum hydroxide, aluminumphosphate and aluminum sulfate.
 18. The vaccine composition of claim 16,wherein the at least one buffering agent is selected from the groupconsisting of citrate, glycine, histidine, and phosphate.
 19. (canceled)20. The vaccine composition of claim 1, wherein the at least oneglass-forming agent is selected from the group consisting of trehalose,sucrose, ficoll, dextran, sucrose, maltotriose, lactose, mannitol,hydroxyethyl starch, glycine, cyclodextrin, and povidone.
 21. (canceled)22. The vaccine composition of claim 16, wherein the at least oneimmunologically-active co-adjuvant is selected from the group consistingof lipid A, lipid A derivatives, monophosphoryl lipid A, chemicalanalogues of monophosphoryl Lipid A, CpG containing oligonucleotides,TLR-4 agonists, flagellin, flagellins derived from gram negativebacteria, TLR-5 agonists, fragments of flagellins capable of binding toTLR-5 receptors, saponins, analogues of saponins, QS-21, purifiedsaponin fractions, ISCOMS and saponin combinations with sterols andlipids.
 23. The vaccine composition of claim 16, wherein the antigen isselected from or derived from the group consisting of rotavirus, footand mouth disease virus, influenza A virus, influenza B virus, influenzaC virus, H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, H1ON7,human parainfluenza type 2, herpes simplex virus, Epstein-Barr virus,varicella virus, porcine herpesvirus 1, cytomegalovirus, lyssavirus,Bacillus anthracis, anthrax PA and derivatives, poliovirus, Hepatitis A,Hepatitis B, Hepatitis C, Hepatitis E, distemper virus, Venezuelanequine encephalomyelitis, feline leukemia virus, reovirus, respiratorysyncytial virus, Lassa fever virus, polyoma tumor virus, canineparvovirus, papilloma virus, tick borne encephalitis virus, rinderpestvirus, human rhinovirus species, Enterovirus species, Mengovirus,paramyxovirus, avian infectious bronchitis virus, human T-cellleukemia-lymphoma virus 1, human immunodeficiency virus-1, humanimmunodeficiency virus-2, lymphocytic choriomeningitis virus, parvovirusB19, adenovirus, rubella virus, yellow fever virus, dengue virus, bovinerespiratory syncitial virus, corona virus, Bordetella pertussis,Bordetella bronchiseptica, Bordetella parapertussis, Brucella abortis,Brucella melitensis, Brucella suis, Brucella ovis, Brucella species,Escherichia coli, Salmonella species, Salmonella typhi, Streptococci,Vibrio cholera, Vibrio parahaemolyticus, Shigella, Pseudomonas,tuberculosis, avium, Bacille Calmette Guerin, Mycobacterium leprae,Pneumococci, Staphlylococci, Enterobacter species, Rochalimaia henselae,Pasteurella haemolytica, Pasteurella multocida, Chlamydia trachomatis,Chlamydia psittaci, Lymphogranuloma venereum, Treponema pallidum,Haemophilus species, Mycoplasma bovigenitalium, Mycoplasma pulmonis,Mycoplasma species, Borrelia burgdorferi, Legionalla pneumophila,Colstridium botulinum, Corynebacterium diphtheriae, Yersiniaentercolitica, Rickettsia rickettsii, Rickettsia typhi, Rickettsiaprowsaekii, Ehrlichia chaffeensis, Anaplasma phagocytophilum, Plasmodiumfalciparum, Plasmodium vivax, Plasmodium malariae, Schistosomes,trypanosomes, Leishmania species, Filarial nematodes, trichomoniasis,sarcosporidiasis, Taenia saginata, Taenia solium, Leishmania, Toxoplasmagondii, Trichinella spiralis, coccidiosis, Eimeria tenella, Cryptococcusneoformans, Candida albican, Apergillus fumigatus, coccidioidomycosis,Neisseria gonorrhoeae, malaria circumsporozoite protein, malariamerozoite protein, trypanosome surface antigen protein, pertussis,alphaviruses, adenovirus, diphtheria toxoid, tetanus toxoid,meningococcal outer membrane protein, streptococcal M protein, Influenzahemagglutinin, cancer antigen, tumor antigens, toxins, Clostridiumperfringens epsilon toxin, ricin toxin, pseudomonas exotoxin, exotoxins,neurotoxins, cytokines, cytokine receptors, monokines, monokinereceptors, plant pollens, animal dander, and dust mites. 24-25.(canceled)
 26. The method of claim 1, wherein the at least one antigencomprises at least one viral antigen or component derived from a virus.27. The method of claim 26, wherein the at least one viral antigencomprises at least one viral antigen or component derived from a coronavirus, a flavivirus, a human papilloma virus or an alphavirus. 28-30.(canceled)